Clinical Trial Title,NCT number,Trial Locations,lng,lat,Drug
Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal,NCT04390594,"Infectious and Tropical Diseases Department, Fann Hospital, Dakar, Senegal",-17.4641781,14.6947013,HCQ + Azithromycin
Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal,NCT04390594,"Diamniadio Children Hospital, Diamniadio, Senegal",-17.1636608,14.7268344,HCQ + Azithromycin
Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal,NCT04390594,"Dalal Jamm Hospital, Guédiawaye, Senegal",-17.3996674,14.7753661,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital de Urgência e Emergência de Rio Branco, Rio Branco, AC, Brazil",-67.8142476,-9.9653701,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital e Clínica São Roque, Ipiaú, BA, Brazil",-39.7355667,-14.138779,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital da Cidade, Salvador, BA, Brazil",-38.4934735,-12.9571926,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Maternidade São Vicente de Paulo, Barbalha, CE, Brazil",-39.3027232,-7.3119638,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital de Messejana Dr. Carlos Alberto Studart Gomes, Fortaleza, CE, Brazil",-38.498395,-3.8157832,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Unimed Cariri, Juazeiro Do Norte, CE, Brazil",-39.3202759,-7.2073092,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Brasilia, Brasilia, DF, Brazil",-47.8828931,-15.8461712,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Instituto de Cardiologia do Distrito Federal, Brasília, Distrito Federal, Brazil",-47.9357361,-15.802223,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Fundação Social Rural de Colatina, Colatina, Espirito Santo, Brazil",-40.6296641,-19.5400456,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Estadual Jayme dos Santos Neves, Serra, ES, Brazil",-40.22743,-20.200262,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Evangélico de Vila Velha, Vila Velha, ES, Brazil",-40.3431333,-20.3460788,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Secretaria de Estado de Saúde de Goias, Goiânia, GO, Brazil",-49.2253596,-16.7313699,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Santa Casa de Misericórdia de Belo Horizonte Santa Casa de BH, Belo Horizonte, MG, Brazil",-43.9256173,-19.9247413,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Santa Paula, Passos, MG, Brazil",-46.6126084,-20.7135374,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Santa Casa da Misericordia - UTI (São João Del Rey), São João Del Rei, MG, Brazil",-44.2578585,-21.1356146,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Maternidade E Pronto Socorro Santa Lucia Ltda, Poços De Caldas, Minas Gerais, Brazil",-46.5559139,-21.8104355,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Universidade Estadual de Londrina, Londrina, Paraná, Brazil",-51.2003547,-23.3241912,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Adventista de Belém, Belém, Pará, Brazil",-48.4570948,-1.4354138,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Adventista de Belem, Belem, PA, Brazil",-48.4570948,-1.4354138,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Procape - Pronto S.Cardiologico de Pe.Prof.Luiz Tavares-, Recife, PE, Brazil",-34.8872499,-8.0491284,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Liga Paranaense de Combate ao Câncer, Curitiba, PR, Brazil",NA,NA,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Giselda Trigueiro, Natal, Rio Grande Do Norte, Brazil",-35.2260266,-5.7972951,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil",-51.2084876,-30.0250791,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil",-51.2214794,-30.0309242,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Naval Marcílio Dias, Rio de Janeiro, RJ, Brazil",-43.2833747,-22.9139074,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital São Lucas, Rio De Janeiro, RJ, Brazil",-43.1928724,-22.9721921,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Maternidade PROMATER, Natal, RN, Brazil",-35.2164318,-5.8235844,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Associação Dr. Bartholomeu Tacchini, Bento Gonçalves, RS, Brazil",-51.5108022,-29.1785725,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Geral de Caxias do Sul, Caxias Do Sul, RS, Brazil",-51.1562243,-29.1611805,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Bruno Born, Lajeado, RS, Brazil",-51.9665968,-29.4631429,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital São Vicente de Paulo, Passo Fundo, RS, Brazil",-52.4132574,-28.2602733,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Maestri E Kormann Consultoria Medico-Cientifica, Blumenau, Santa Catarina, Brazil",-49.0682555,-26.8801569,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Sociedade Literaria e Caritativa Santo Agostinho, Criciúma, Santa Catarina, Brazil",-49.3647909,-28.6744759,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Nereu Ramos, Florianópolis, SC, Brazil",-48.533927,-27.577689,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Universitário Polydoro Ernani de São Thiago/HU - UFSC, Florianópolis, SC, Brazil",-48.5183146,-27.5973897,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Centro Hospitalar Unimed, Joinville, SC, Brazil",-48.845416,-26.289832,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Dona Helena, Joinville, SC, Brazil",-48.850613,-26.299132,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Municipal Sao Jose, Joinville, SC, Brazil",-48.8462325,-26.309458,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Regional Hans Dieter Schmidt, Joinville, SC, Brazil",-48.8127529,-26.2833356,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Faculdade de Medicina de Botucatu, Botucatu, SP, Brazil",-48.4943054,-22.8911069,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"nstituto de Pesquisa Clínica de Campinas, Campinas, SP, Brazil",-47.1110025,-22.9199564,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Fundação do ABC (Hospital Estadual Mário Covas), Santo André, SP, Brazil",-46.5331357,-23.6709183,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"AC Camargo Cancer Center - Fundação Antonio Prudente, São Paulo, SP, Brazil",-46.6367384,-23.5631726,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Casa de Saude Santa Marcelina, São Paulo, SP, Brazil",-46.3844534,-23.5115075,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Alemão Oswaldo Cruz, São Paulo, SP, Brazil",-46.6435635,-23.5690595,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Moriah, São Paulo, SP, Brazil",-46.6602778,-23.615,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Nove de Julho, São Paulo, SP, Brazil",-46.6553318,-23.5594056,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Santa Paula, São Paulo, SP, Brazil",-46.6757416,-23.6056726,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital São Camilo Pompeia, São Paulo, SP, Brazil",-46.6882049,-23.5342634,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Fundação Pio XII, Barretos, São Paulo, Brazil",-48.5706322,-20.5536637,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Santa Casa de Misericordia de Votuporanga, Votuporanga, São Paulo, Brazil",-49.9780348,-20.4263441,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Israelita Albert Einstein, São Paulo, Brazil",-46.7152547,-23.5999606,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Associacao Beneficente Siria, São Paulo, Brazil",-46.6165824,-23.4452612,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Hospital Vila Santa Catarina, São Paulo, Brazil",-46.6535155,-23.6571408,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil",-46.6419505,-23.5664177,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil",-46.6419505,-23.5664177,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Secretaria de Saúde do Estado de São Paulo, São Paulo, Brazil",-46.6684843,-23.5552521,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Serv Social da Industria do papel, papelão e cortiça do estado de SP, São Paulo, Brazil",-46.6276663,-23.5950111,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Sociedade Beneficente de Senhoras Hospital Sírio-Libanês, São Paulo, Brazil",-46.6528642,-23.5313723,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),NCT04321278,"Universidade Federal de São Paulo, São Paulo, Brazil",-46.6489943,-23.5916438,HCQ + Azithromycin
Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients,NCT04374903,"King Hussein Cancer Center, Amman, Jordan",35.8749208,32.0044797,HCQ + Azithromycin
Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial),NCT04345861,"Montpellier University hospital, Montpellier, France",3.8248185,43.6363429,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital Geral Clériston Andrade, Feira De Santana, BA, Brazil",-38.9404,-12.277271,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital Ana Nery - HAN/SESAB, Salvador, BA, Brazil",-38.4959327,-12.9572223,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"HHospital SAMUR, Vitória Da Conquista, BA, Brazil",-40.8460076,-14.8626279,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital Geral de Vitória da Conquista, Vitória Da Conquista, BA, Brazil",-40.8502201,-14.8789474,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital de Brasília, Brasilia, DF, Brazil",-47.8699039,-15.7651574,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Instituto de Cardiologia do Distrito Federal, Brasília, DF, Brazil",-47.9357361,-15.802223,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital Maternidade São José - UNESC - Fundação Social Rural de Colatina, Colatina, ES, Brazil",-40.6296641,-19.5400456,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital Vila da Serra, Nova Lima, MG, Brazil",-43.9441692,-19.9803381,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Santa Casa de Misericórdia de São João Del Rei, São João Del Rei, MG, Brazil",-44.2578585,-21.1356146,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Associação Evangélica Beneficente de Londrina - Hospital Evangélico de Londrina, Londrina, PR, Brazil",-51.1606506,-23.3266892,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Instituto Estadual do Cérebro Paulo Niemeyer, Rio De Janeiro, RJ, Brazil",-43.1876578,-22.913457,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital Geral de Caxias do Sul, Caxias do Sul, RS, Brazil",-51.1562243,-29.1611805,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital Santa Rita - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil",-51.2214794,-30.0309242,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital São Francisco - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil",-51.2214794,-30.0309242,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital São José, Criciuma, SC, Brazil",-49.3643241,-28.6744925,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital Baía Sul - Baía Sul Medical Center, Florianópolis, SC, Brazil",-48.5449549,-27.6011594,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital Nereu Ramos, Florianópolis, Sc, Brazil",-48.533927,-27.577689,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Centro Hospitalar Unimed, Joinville, SC, Brazil",-48.845416,-26.289832,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital de Amor - Unidade Barretos (Fundação PIO XII), Barretos, SP, Brazil",-48.5717864,-20.5545292,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Casa de Saúde Santa Marcelina, São Paulo, SP, Brazil",-46.4335116,-23.504914,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital Albert Einstein, São Paulo, SP, Brazil",-46.7152547,-23.5999606,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital Beneficência Portuguesa - Real e Benemérita Associação Portuguesa de Beneficência, São Paulo, SP, Brazil",-46.6419505,-23.5664177,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital BP Mirante - Real e Benemérita, São Paulo, SP, Brazil",-46.6431081,-23.5674333,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital das Clínicas da FMUSP, São Paulo, SP, Brazil",-46.6698263,-23.5571357,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital do Servidor Público Estadual - HSPE - IAMSPE, São Paulo, SP, Brazil",-46.6540085,-23.5969896,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital São Paulo - UNIFESP, São Paulo, SP, Brazil",-46.643593,-23.5975138,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital Sírio-Libanês, São Paulo, SP, Brazil",-46.6748267,-23.5849389,HCQ + Azithromycin
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),NCT04322123,"Hospital SEPACO, São Paulo, S, Brazil",-46.6276882,-23.5951605,HCQ + Azithromycin
"Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to ""no Treatment"" in SARS CoV 2 Virus",NCT04355052,"Sheba Medical Center, Ramat Gan, Israel",34.842852,32.04671,HCQ + Azithromycin
"Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to ""no Treatment"" in SARS CoV 2 Virus",NCT04355052,"Sheba Medical Center, Tel HaShomer, Israel",34.842852,32.04671,HCQ + Azithromycin
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,NCT04358081,"Novartis Investigative Site, Los Angeles, California, United States",-118.2436849,34.0522342,HCQ + Azithromycin
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,NCT04358081,"Novartis Investigative Site, San Francisco, California, United States",-122.3955966,37.7689296,HCQ + Azithromycin
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,NCT04358081,"Novartis Investigative Site, Gainesville, Florida, United States",-82.3248262,29.6516344,HCQ + Azithromycin
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,NCT04358081,"Novartis Investigative Site, Chicago, Illinois, United States",-87.6276182,41.8886599,HCQ + Azithromycin
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,NCT04358081,"Novartis Investigative Site, Baton Rouge, Louisiana, United States",-91.1871466,30.4514677,HCQ + Azithromycin
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,NCT04358081,"Novartis Investigative Site, Baltimore, Maryland, United States",-76.6121893,39.2903848,HCQ + Azithromycin
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,NCT04358081,"Novartis Investigative Site, Baltimore, Maryland, United States",-76.6121893,39.2903848,HCQ + Azithromycin
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,NCT04358081,"Novartis Investigative Site, Columbia, Missouri, United States",-92.3340724,38.9517053,HCQ + Azithromycin
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,NCT04358081,"Novartis Investigative Site, Chapel Hill, North Carolina, United States",-79.0558445,35.9131996,HCQ + Azithromycin
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,NCT04358081,"Novartis Investigative Site, Seattle, Washington, United States",-122.3320708,47.6062095,HCQ + Azithromycin
A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19,NCT04347031,"Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation",37.6172999,55.755826,HCQ + Azithromycin
Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial,NCT04365231,"Hopital Saint Joseph, Marseille, Paca, France",5.3933001,43.2753932,HCQ + Azithromycin
Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19,NCT04329832,"Intermountain Medical Center, Murray, Utah, United States",-111.8950267,40.6579289,HCQ + Azithromycin
Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19,NCT04329832,"University of Utah, Salt Lake City, Utah, United States",-111.8421021,40.7649368,HCQ + Azithromycin
Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19,NCT04334382,"Intermountain Medical Center, Murray, Utah, United States",-111.8950267,40.6579289,HCQ + Azithromycin
Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19,NCT04334382,"University of Utah, Salt Lake City, Utah, United States",-111.8421021,40.7649368,HCQ + Azithromycin
"Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO",NCT04341870,"AP-HP Hôpital Avicenne, Bobigny, France",2.4239471,48.9146194,HCQ + Azithromycin
"Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO",NCT04341870,"AP-HP Hôpital Ambroise Paré, Boulogne-Billancourt, France",2.2354935,48.8492607,HCQ + Azithromycin
"Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO",NCT04341870,"AP-HP Hôpital Beaujon, Clichy, France",2.3083004,48.9082554,HCQ + Azithromycin
"Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO",NCT04341870,"AP-HP Hôpital Pitié Salpétrière, Paris, France",2.3650429,48.8370792,HCQ + Azithromycin
"Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO",NCT04341870,"AP-HP Hôpital Saint Antoine, Paris, France",2.3827263,48.8488116,HCQ + Azithromycin
Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19,NCT04348474,"Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil",-46.6322189,-23.6181027,HCQ + Azithromycin
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,NCT04336332,"Saint Barnabas Medical Center, Livingston, New Jersey, United States",-74.3036941,40.7637521,HCQ + Azithromycin
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,NCT04336332,"Monmouth Medical Center, Long Branch, New Jersey, United States",-73.9854333,40.2954704,HCQ + Azithromycin
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,NCT04336332,"Morristown Medical Center, Morristown, New Jersey, United States",-74.4656519,40.7894006,HCQ + Azithromycin
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,NCT04336332,"Robert Wood Johnson University Hopsital, New Brunswick, New Jersey, United States",-74.450131,40.4952121,HCQ + Azithromycin
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,NCT04336332,"Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States",-74.4486555,40.4965117,HCQ + Azithromycin
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,NCT04336332,"The University Hospital, Newark, New Jersey, United States",-74.1910884,40.7406294,HCQ + Azithromycin
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,NCT04336332,"Overlook Hospital, Summit, New Jersey, United States",-74.3536318,40.7127936,HCQ + Azithromycin
An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19,NCT04346693,"Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation",37.6172999,55.755826,HCQ + Azithromycin
Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19,NCT04329572,"Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil",-46.6322189,-23.6181027,HCQ + Azithromycin
"Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19",NCT04359953,"CHU de Strasbourg, Strasbourg, France",7.7462879,48.5764648,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Alabama CRS, Birmingham, Alabama, United States",-86.8056842,33.5029685,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"UCLA CARE Center CRS, Los Angeles, California, United States",-118.4031397,34.0539099,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"University of Southern California CRS, Los Angeles, California, United States",-118.285117,34.0223519,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"UCSD Antiviral Research Center CRS, San Diego, California, United States",-117.1658249,32.7555263,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Ucsf Hiv/Aids Crs, San Francisco, California, United States",-122.4561704,37.7641739,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Harbor-UCLA CRS, Torrance, California, United States",-118.2947364,33.8298404,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"University of Colorado Hospital CRS, Aurora, Colorado, United States",-104.8420288,39.7426294,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Whitman-Walker Health CRS, Washington, District of Columbia, United States",-77.0315469,38.9104557,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"The Ponce de Leon Center CRS, Atlanta, Georgia, United States",-84.3761076,33.771853,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Northwestern University CRS, Chicago, Illinois, United States",-87.6168769,41.8960678,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Rush University CRS, Chicago, Illinois, United States",-87.668852,41.8735131,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Massachusetts General Hospital CRS (MGH CRS), Boston, Massachusetts, United States",-71.067566,42.3626109,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey, United States",-74.189656,40.7400804,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Weill Cornell Chelsea CRS, New York, New York, United States",-73.9932413,40.7441606,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Weill Cornell Uptown CRS, New York, New York, United States",-73.954897,40.7649151,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"University of Rochester Adult HIV Therapeutic Strategies Network CRS, Rochester, New York, United States",-77.6227808,43.1223345,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Chapel Hill CRS, Chapel Hill, North Carolina, United States",-79.0469134,35.9049122,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Greensboro CRS, Greensboro, North Carolina, United States",-79.7919754,36.0726354,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Cincinnati Clinical Research Site, Cincinnati, Ohio, United States",-84.4675849,39.1473527,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Case Clinical Research Site, Cleveland, Ohio, United States",-81.620474,41.504468,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Ohio State University CRS, Columbus, Ohio, United States",-83.0306222,40.0068363,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Penn Therapeutics, CRS, Philadelphia, Pennsylvania, United States",-75.1932137,39.9522188,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"University of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States",-79.960835,40.4443533,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"The Miriam Hospital Clinical Research Site (TMH CRS) CRS, Providence, Rhode Island, United States",-71.398257,41.851722,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Vanderbilt Therapeutics (VT) CRS, Nashville, Tennessee, United States",-86.8026551,36.1447034,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Trinity Health and Wellness Center CRS, Dallas, Texas, United States",-96.8254278,32.744499,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"University of Washington AIDS CRS, Seattle, Washington, United States",-122.3035199,47.6553351,HCQ + Azithromycin
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,NCT04358068,"Puerto Rico AIDS Clinical Trials Unit CRS, San Juan, Puerto Rico",-66.0522082,18.3966848,HCQ + Azithromycin
Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients,NCT04341207,"Gustave Roussy, Villejuif, Val De Marne, France",2.3484483,48.7942588,HCQ + Azithromycin
Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE),NCT04392128,"Institut de Cancérologie Strasbourg Europe, Strasbourg, France",7.7093834,48.5940073,HCQ + Azithromycin
Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting,NCT04370782,"St Francis Hospital, Roslyn, New York, United States",-73.6702617,40.8046832,HCQ + Azithromycin
"Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19",NCT04332094,"Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",2.174314,41.4136997,HCQ + Azithromycin
"Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection",NCT04335552,"Duke Regional Hospital, Durham, North Carolina, United States",-78.9009425,36.036161,HCQ + Azithromycin
"Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection",NCT04335552,"Duke University Hospital, Durham, North Carolina, United States",-78.938442,36.0075052,HCQ + Azithromycin
"Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection",NCT04335552,"Durham VA Medical Center, Durham, North Carolina, United States",-78.9386528,36.0090122,HCQ + Azithromycin
"Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection",NCT04335552,"Duke Raleigh Hospital, Raleigh, North Carolina, United States",-78.618179,35.8282966,HCQ + Azithromycin
Azithromycin in Hospitalized COVID-19 Patients,NCT04359316,"Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of",51.3980673,35.8001144,HCQ + Azithromycin
Effectiveness of Hydroxychloroquine in Covid-19 Patients,NCT04328272,"Ayub Teaching Institution, Abbottābād, K.p.k, Pakistan",73.2364723,34.2039639,HCQ + Azithromycin
Asymptomatic COVID-19 Trial,NCT04374552,"Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States",-74.450131,40.4952121,HCQ + Azithromycin
Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 Patients,NCT04354597,"King Hussein Cancer Center, Amman, Jordan",35.8749208,32.0044797,HCQ + Azithromycin
Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus,NCT04344379,"Hopial Avicenne, Bobigny, France",2.4239471,48.9146194,HCQ + Azithromycin
Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus,NCT04344379,"Hôpital GHU Paris Saclay, Le Kremlin-Bicêtre, France",2.3522501,48.8105963,HCQ + Azithromycin
Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus,NCT04344379,"Hôpital Saint Antoine, Paris, France",2.3827263,48.8488116,HCQ + Azithromycin
Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus,NCT04344379,"Hôpital Broca, Paris, France",2.347284,48.834292,HCQ + Azithromycin
Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus,NCT04344379,"Hôpital La Pitié-Salpétrière, Paris, France",2.3650429,48.8370792,HCQ + Azithromycin
Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus,NCT04344379,"Hôpital Cochin, Paris, France",2.3402667,48.8368937,HCQ + Azithromycin
Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus,NCT04344379,"Hôpital européen Georges Pompidou, Paris, France",2.2727176,48.8396882,HCQ + Azithromycin
Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus,NCT04344379,"Hôpital Necker, Paris, France",2.3147044,48.845868,HCQ + Azithromycin
Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19),NCT04361461,"Apsen Farmacêutica S.A., São Paulo, Brazil",-46.7104346,-23.6477874,HCQ + Azithromycin
VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL),NCT04363203,"San Francisco VA, San Francisco, California, United States",-122.5052644,37.782395,HCQ + Azithromycin
Novel Agents for Treatment of High-risk COVID-19 Positive Patients,NCT04374019,"University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States",-84.5073963,38.0311683,HCQ + Azithromycin
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,NCT04322396,"Aalborg Sygehus, Aalborg, Denmark",9.9101091,57.0386022,HCQ + Azithromycin
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,NCT04322396,"Bispebjerg Hospital, Copenhagen, Denmark",12.5401313,55.7140142,HCQ + Azithromycin
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,NCT04322396,"Herlev-Gentofte Hospital, Copenhagen, Denmark",12.5467355,55.7388664,HCQ + Azithromycin
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,NCT04322396,"Hvidovre Hospital, Copenhagen, Denmark",12.470292,55.648779,HCQ + Azithromycin
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,NCT04322396,"Nordsjællands Hospital, Hillerød, Denmark",12.326221,55.930868,HCQ + Azithromycin
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,NCT04322396,"Odense Universitetshospital, Odense, Denmark",10.3675736,55.3850091,HCQ + Azithromycin
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,NCT04322396,"Roskilde Sygehus, Roskilde, Denmark",12.0903485,55.6361646,HCQ + Azithromycin
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,NCT04322396,"Slagelse Sygehus, Slagelse, Denmark",11.370371,55.400234,HCQ + Azithromycin
"Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19",NCT04344457,"Perseverance Research Center, Scottsdale, Arizona, United States",-111.9264707,33.5871371,HCQ + Azithromycin
"Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19",NCT04344457,"Covidcraz 19, Llc, New Orleans, Louisiana, United States",-90.0715323,29.9510658,HCQ + Azithromycin
Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease,NCT04344444,"University Medical Center New Orleans, New Orleans, Louisiana, United States",-90.0814661,29.960568,HCQ + Azithromycin
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Hospital Universitario de Neiva, Neiva, Huila, Colombia",-75.2811942,2.9321351,HCQ + Azithromycin
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Clínica Reina Sofía, Bogotá, Colombia",-74.0519893,4.7068994,HCQ + Azithromycin
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Fundacion Cardio Infantil, Bogotá, Colombia",-74.0345157,4.7413984,HCQ + Azithromycin
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Hospital Universitario San Ignacio, Bogotá, Colombia",-74.0640042,4.6282546,HCQ + Azithromycin
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Clinica Universitaria Colombia, Bogotá, Colombia",-74.1065512,4.6482242,HCQ + Azithromycin
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Hospital Universitario Nacional de Colombia, Bogotá, Colombia",-74.0957156,4.6489485,HCQ + Azithromycin
A Randomised Controlled Trial of Early Intervention in COVID-19: Favipiravir Verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe,NCT04373733,"Chelsea and Westminster Hospital, London, United Kingdom",-0.182401,51.4849533,HCQ + Azithromycin
A Randomised Controlled Trial of Early Intervention in COVID-19: Favipiravir Verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe,NCT04373733,"West Middlesex University Hospital, London, United Kingdom",-0.3243212,51.4736289,HCQ + Azithromycin
Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+),NCT04351919,"Eshmoun Clinical Research Centre/ Hôpital Abderrahmen Mami-Ariana, Tunis, Tunisia",10.1782429,36.8698022,HCQ + Azithromycin
Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial,NCT04339816,"František Duška, Praha, Česká Republika, Czechia",14.4378005,50.0755381,HCQ + Azithromycin
"Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection",NCT04341727,"Washington University School of Medicine Infectious Disease Clinical Research Unit, Saint Louis, Missouri, United States",-90.2590677,38.6345957,HCQ + Azithromycin
"Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection",NCT04341727,"Washington University School of Medicine, Saint Louis, Missouri, United States",-90.2629289,38.6351441,HCQ + Azithromycin
Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19,NCT04411433,"Hacettepe University, School of Medicine, Ankara, Turkey",32.8631625,39.9303672,HCQ + Azithromycin
A Study of Quintuple Therapy to Treat COVID-19 Infection,NCT04334512,"ProgenaBiome, Ventura, California, United States",-119.2210602,34.2566277,HCQ + Azithromycin
Bacteriotherapy in the Treatment of COVID-19,NCT04368351,"Department of Public Heath and Infectious Diseases. University of Rome ""Sapienza"" (Italy), Rome, Italy",12.5144384,41.9037626,HCQ + Azithromycin
Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19,NCT04390152,"Clinical Somer, Rionegro, Antioquia, Colombia",-75.3775164,6.1406917,HCQ + Azithromycin
Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit,NCT04363060,"Chu Angers, Angers, France",-0.5548297,47.4815099,HCQ + Azithromycin
Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit,NCT04363060,"CHD Vendée, La Roche-sur-Yon, France",-1.4118805,46.6677714,HCQ + Azithromycin
Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit,NCT04363060,"CHU Poitiers, Poitiers, France",0.3849052,46.5589271,HCQ + Azithromycin
Double Therapy With IFN-beta 1b and Hydroxychloroquine,NCT04350281,"The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong",114.1312557,22.2701076,HCQ + Azithromycin
Hydroxychloroquine for COVID-19,NCT04342221,"Institute for Tropical Medicine, Tübingen, Germany",9.0576448,48.5216364,HCQ + Azithromycin
Treatment for COVID-19 in High-Risk Adult Outpatients,NCT04354428,"Ruth M. Rothstein CORE Center - Cook County Health, Chicago, Illinois, United States",-87.6771887,41.8746646,HCQ + Azithromycin
Treatment for COVID-19 in High-Risk Adult Outpatients,NCT04354428,"Tulane University, New Orleans, Louisiana, United States",-90.1203167,29.9407282,HCQ + Azithromycin
Treatment for COVID-19 in High-Risk Adult Outpatients,NCT04354428,"Boston University, Boston, Massachusetts, United States",-71.1053991,42.3504997,HCQ + Azithromycin
Treatment for COVID-19 in High-Risk Adult Outpatients,NCT04354428,"NYU Langone Health, New York, New York, United States",-73.9722693,40.746844,HCQ + Azithromycin
Treatment for COVID-19 in High-Risk Adult Outpatients,NCT04354428,"SUNY Upstate Medical University, Syracuse, New York, United States",-76.1395979,43.0422979,HCQ + Azithromycin
Treatment for COVID-19 in High-Risk Adult Outpatients,NCT04354428,"University of Washington Coordinating Center, Seattle, Washington, United States",-122.3035199,47.6553351,HCQ + Azithromycin
Treatment for COVID-19 in High-Risk Adult Outpatients,NCT04354428,"UW Virology Research Clinic, Seattle, Washington, United States",-122.3182835,47.6588389,HCQ + Azithromycin
Patient Preference Trial for COVID-19 (PPT-COVID),NCT04418193,"Centre Hospitalier Princesse Grace, Monaco, Monaco",7.4126981,43.7307715,HCQ + Azithromycin
Efficacy of Ivermectin as Add on Therapy in COVID19 Patients,NCT04343092,"General Directorate of Medical City, Bagdad, Baghdad, Iraq",44.3755185,33.3458996,HCQ + Azithromycin
OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome,NCT04365582,"Hôpital Privé d'Antony, Antony, France",2.302302,48.7567574,HCQ + Azithromycin
OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome,NCT04365582,"Hôpital Avicenne, Bobigny, France",2.4250233,48.9158686,HCQ + Azithromycin
OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome,NCT04365582,"Centre Hospitalier Intercommunal de Créteil, Créteil, France",2.4654319,48.7964094,HCQ + Azithromycin
OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome,NCT04365582,"Groupe Hospitalier Paris Saint-Joseph, Paris, France",2.3103313,48.829771,HCQ + Azithromycin
OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome,NCT04365582,"Institut Mutualiste Montsouris, Paris, France",2.3327172,48.822009,HCQ + Azithromycin
Study of Biomarkers in the Long-term Impact of Coronavirus Infection in the Cardiorespiratory System,NCT04353245,"Instituto do Coração - Hospital das Clínicas - Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil",-46.6698263,-23.5571357,HCQ + Azithromycin
Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora,NCT04366089,"Francesco Pugliese, Rome, RM, Italy",12.5134687,41.9627606,HCQ + Azithromycin
Randomised Evaluation of COVID-19 Therapy,NCT04381936,"Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom",-1.2151574,51.7516232,HCQ + Azithromycin
Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial,NCT04324463,"Hamilton Health Sciences, Hamilton, Ontario, Canada",-79.8457682,43.2401034,HCQ + Azithromycin
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,NCT04398004,"COVID-19 Department, General Hospital of Attica SISMANOGLEIO-AMALIA FLEMING, Marousi, Athens, Greece",23.828466,38.0463484,HCQ + Azithromycin
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,NCT04398004,"2nd Department of Internal Medicine, General Hospital of Nikaia, Piraeus, Attica, Greece",23.6423642,37.9701123,HCQ + Azithromycin
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,NCT04398004,"2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece",25.873962,40.8457193,HCQ + Azithromycin
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,NCT04398004,"1st University Department of Internal Medicine, LAIKO General Hospital of Athens, Athens, Greece",23.7653267,37.9833862,HCQ + Azithromycin
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,NCT04398004,"2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens, Athens, Greece",23.7275388,37.9838096,HCQ + Azithromycin
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,NCT04398004,"3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece",23.7793555,37.9950485,HCQ + Azithromycin
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,NCT04398004,"1st Department of Internal Medicine, General University Hospital of Ioannina, Ioánnina, Greece",20.8424173,39.620779,HCQ + Azithromycin
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,NCT04398004,"2nd Department of Internal Medicine, General Hospital of Piraeus ""Tzaneio"", Piraeus, Greece",23.6454905,37.9343495,HCQ + Azithromycin
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,NCT04398004,"1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Thessaloníki, Greece",22.9600672,40.629556,HCQ + Azithromycin
Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus,NCT04323345,"Mahmoud Tantawy, Cairo, Egypt",31.2522411,30.053749,HCQ + Azithromycin
Efficacy of Ivermectin as Add on Therapy in COVID19 Patients,NCT04343092,"General Directorate of Medical City, Bagdad, Baghdad, Iraq",44.3755185,33.3458996,Ivermectin
Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study,NCT04373824,"Max Super Speciality hospital, Saket (A unit of Devki Devi Foundation), New Delhi, Delhi, India",77.2120291,28.527476,Ivermectin
Efficacy of Ivermectin in COVID-19,NCT04392713,"Combined Military Hospital Lahore, Lahore, Punjab, Pakistan",74.3726762,31.5408931,Ivermectin
Ivermectin and Doxycycine in COVID-19 Treatment,NCT04403555,"Sherief Abd-Elsalam, Tanta, Egypt",31.0023174,30.8055576,Ivermectin
Prophylactic Ivermectin in COVID-19 Contacts,NCT04422561,"Zagazig University, Zagazig, Sharkia, Egypt",31.4831937,30.5883084,Ivermectin
The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment,NCT04351347,"Tanta University, Tanta, Egypt",30.9991409,30.7924391,Ivermectin
Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19,NCT04399746,"Outpatient treatment, Mexico City, Mexico",-99.133208,19.4326077,Ivermectin
Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19,NCT04381884,"Centro de Educación Médica e Investigaciones Clínicas ""Norberto Quirno"" CEMIC, Buenos Aires, Ciudad De Buenos Aires, Argentina",-58.4053845,-34.5952261,Ivermectin
Trial to Promote Recovery From COVID-19 With Ivermectin or Endocrine Therapy,NCT04374279,"Johns Hopkins Hospital, Baltimore, Maryland, United States",-76.5927362,39.2967385,Ivermectin
New Antiviral Drugs for Treatment of COVID-19,NCT04392427,"Mansoura University, Mansoura, Select A State Or Province, Egypt",31.3589223,31.0409949,Ivermectin
Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection,NCT04391127,"Jose Manuel Arreola Guerra, Aguascalientes, Mexico",-102.2598747,21.9140456,Ivermectin
Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,NCT04390022,"Clinica Universidad de Navarra, Pamplona, Navarra, Spain",-1.663439,42.805408,Ivermectin
Novel Agents for Treatment of High-risk COVID-19 Positive Patients,NCT04374019,"University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States",-84.5073963,38.0311683,Ivermectin
A Real-life Experience on Treatment of Patients With COVID 19,NCT04345419,"Tanta university hospital, Tanta, Egypt",30.9951138,30.8015015,Ivermectin
"Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections",NCT04365725,"Hôpital Cochin, Paris, France",2.3402667,48.8368937,Remdesivir
Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19,NCT04410354,"Mayo Clinic in Arizona, Phoenix, Arizona, United States",-111.9544986,33.6583608,Remdesivir
Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19,NCT04410354,"Mayo Clinic in Florida, Jacksonville, Florida, United States",-81.4451456,30.2626481,Remdesivir
Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19,NCT04410354,"Mayo Clinic, Rochester, Minnesota, United States",-92.4668833,44.0226255,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States",-117.8441325,33.8520823,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Alta Bates Summit Medical Center, Berkeley, California, United States",-122.2688043,37.8642168,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Mills-Peninsula Medical Center, Burlingame, California, United States",-122.3824274,37.5923049,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Eden Medical Center, Castro Valley, California, United States",-122.0888289,37.6979825,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States",-118.1288238,33.9191479,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States",-117.4323129,34.0723526,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"St Joseph Hospital Eureka, Fortuna, California, United States",-124.1424555,40.7839616,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States",-118.2957816,33.7886375,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States",-118.293899,34.0984583,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States",-118.3750021,34.0383728,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States",-118.5896036,34.1709445,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Mission Hospital Regional Medical Center, Mission Viejo, California, United States",-117.6653709,33.5610031,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Los Angeles Medical Center, 27300 Iris Avenue, Moreno Valley, California, United States",-117.186026,33.897404,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"El Camino Hospital, Mountain View, California, United States",-122.0795279,37.3691517,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States",-117.9296357,33.624397,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Oakland Medical Center, Oakland, California, United States",-122.2582441,37.8235196,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States",-117.6086894,34.0324565,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States",-117.86362,33.779675,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Los Angeles Medical Center, 13651 Willard Street, Panorama City, California, United States",-118.4302294,34.2189257,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Riverside, California, United States",-117.4694322,33.905076,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States",-121.2495341,38.765635,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Sutter Medical Center Sacramento, Sacramento, California, United States",-121.4694362,38.5713948,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States",-117.0951878,32.7913395,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States",-117.1251884,32.8297116,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Oakland Medical Center, 1200 El Camino Real, San Francisco, California, United States",-122.4385597,37.6587814,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States",-122.432128,37.7905249,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Oakland Medical Center, 2425 Geary Blvd, San Francisco, California, United States",-122.4429971,37.7824144,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Oakland Medical Center, 250 Hospital Parkway, Suite 850, San Jose, California, United States",-121.8002512,37.2398041,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Oakland Medical Center, 2500 Merced St, San Leandro, California, United States",-122.1647052,37.7064867,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Oakland Medical Center, 700 Lawrence Expressway, Santa Clara, California, United States",-121.9988333,37.3360472,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Providence St. Johns Medical Center, Santa Monica, California, United States",-118.4796445,34.0307739,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States",-122.7510442,38.4952463,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Stanford Hospital, Stanford, California, United States",-122.1758669,37.4347593,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States",-104.8375727,39.7452818,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States",-104.9715971,39.7464498,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"SCL Health St. Joseph Hospital, Denver, Colorado, United States",-104.9715971,39.7464498,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Rose Medical Center, Denver, Colorado, United States",-104.9335815,39.7319823,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States",-105.086874,39.9699702,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Yale-New Haven Hospital, New Haven, Connecticut, United States",-72.9352096,41.3020731,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States",-157.9000128,21.3632544,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States",-87.67369,41.8728476,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Rush University Medical Center, Chicago, Illinois, United States",-87.6674637,41.8747917,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"University of Chicago, Chicago, Illinois, United States",-87.5987133,41.7886079,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"IU Health Methodist Hospital, Indianapolis, Indiana, United States",-86.1633559,39.7903409,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States",-91.547979,41.658974,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Tulane University, New Orleans, Louisiana, United States",-90.1203167,29.9407282,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Maine Medical Center, Portland, Maine, United States",-70.276399,43.6531739,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Holy Cross Hospital, Silver Spring, Maryland, United States",-77.0347487,39.0147079,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Tufts Medical Center, Boston, Massachusetts, United States",-71.0627826,42.3495371,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States",-71.1074884,42.3361091,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",-71.1049051,42.3397365,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States",-83.7278795,42.283286,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Henry Ford Health System, Detroit, Michigan, United States",-83.0758102,42.3635022,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hennepin Healthcare, Minneapolis, Minnesota, United States",-93.2615378,44.9722477,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Mayo Clinic, Rochester, Minnesota, United States",-92.4668833,44.0226255,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States",-114.0000297,46.8755594,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States",-72.2729872,43.675364,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hackensack University Medical Center, Hackensack, New Jersey, United States",-74.0564882,40.8840343,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States",-74.5952861,40.5683581,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States",-74.450131,40.4952121,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States",-74.2125193,40.7100492,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"St. Joseph's University Medical Center, Paterson, New Jersey, United States",-74.1653704,40.9028953,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Jacobi Medical Center, Bronx, New York, United States",-73.8463639,40.855993,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"James J. Peters Veterans Administration Medical Center, Bronx, New York, United States",-73.9064045,40.8674032,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Jamaica Hospital Medical Center, Jamaica, New York, United States",-73.8166244,40.7003783,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Danbury Hospital, Lagrangeville, New York, United States",-73.4451577,41.4054443,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"North Shore University Hospital, Manhasset, New York, United States",-73.7013309,40.7752276,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"North Shore University Hospital, 270-05 76th Ave, New Hyde Park, New York, United States",-73.7073828,40.7543773,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States",-73.9533616,40.7898695,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States",-73.9533616,40.7898695,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States",-73.9533616,40.7898695,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Icahn School of Medicine at Mount Sinai, New York, New York, United States",-73.9533616,40.7898695,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Columbia University Medical Center-New York Presbyterian Hospital, New York, New York, United States",-73.941459,40.8409549,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, United States",-73.9542869,40.7643076,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Duke University Medical Center, Durham, North Carolina, United States",-78.9371331,36.0058487,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",-81.6060645,41.5052505,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States",-122.8767439,45.5394714,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Providence Portland Medical Center, Portland, Oregon, United States",-122.6127272,45.5275562,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Providence St. Vincent Medical Center, Portland, Oregon, United States",-122.771627,45.5104546,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaiser Sunnyside Medical Center, Portland, Oregon, United States",-122.5601232,45.4314461,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States",-75.1938829,39.9501477,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",-75.1938829,39.9501477,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Temple University Hospital, Philadelphia, Pennsylvania, United States",-75.1507582,40.0050435,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"The Miriam Hospital, Providence, Rhode Island, United States",-71.398257,41.851722,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Prisma Health Richland Hospital, Columbia, South Carolina, United States",-81.0333789,34.0279493,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Prisma Health Richland Hospital, 701 Grove Road, Greenville, South Carolina, United States",-82.4109998,34.818455,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States",-96.82346,32.7608903,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States",-96.8350262,32.8086365,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Baylor University Medical Center, Dallas, Texas, United States",-96.779048,32.7896805,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States",-96.8350262,32.8086365,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States",-96.8419366,32.8173287,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States",-97.345412,32.7296877,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Houston Methodist Hospital, Houston, Texas, United States",-95.399568,29.7106626,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States",-97.3640532,31.0779405,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"University of Utah Health, Salt Lake City, Utah, United States",-111.8366784,40.7715716,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Virginia Hospital Center, Arlington, Virginia, United States",-77.127521,38.8891114,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Inova Fairfax Medical Campus, Falls Church, Virginia, United States",-77.2281251,38.8573966,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"VCU Health Medical Center, Richmond, Virginia, United States",-77.4299508,37.5408047,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Providence Regional Medical Center Everett, Everett, Washington, United States",-122.2052146,48.0000596,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kadlec Regional Medical Center, Kennewick, Washington, United States",-119.2822234,46.2813864,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Providence St. Peter Hospital, Olympia, Washington, United States",-122.8479904,47.0529957,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Virginia Mason Medical Center, Seattle, Washington, United States",-122.3277093,47.6099974,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Swedish Center for Comprehensive Care, Seattle, Washington, United States",-122.3214872,47.6063315,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"MultiCare Deaconess Hospital, Spokane, Washington, United States",-117.4235336,47.6517794,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"MultiCare Tacoma General Hospital, Tacoma, Washington, United States",-122.4529736,47.2593705,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"St Joseph Medical Center, Tacoma, Washington, United States",-122.4478581,47.2453583,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China",113.261861,23.113169,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"CHU Pellegrin, Bordeaux, France",-0.6043875,44.8274249,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"CHU de Montpellier-Hopital Gui de Chauliac, Montpelier Cedex 5, France",3.8623414,43.6301844,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"CHU de Nantes-Hotel Dieu, Nantes, France",-1.5545498,47.2107575,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hopital Saint-Louis, Paris, France",2.3672856,48.8771612,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hopital Saint Antoine, Paris, France",2.3827263,48.8488116,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany",13.3766245,52.5264618,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Germany",6.7922861,51.195064,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany",9.974533,53.5908116,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany",10.1433156,54.3307016,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany",12.375768,51.385368,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany",11.599781,48.137976,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Klinik für Hämatologie, Onkologie, Immunologie, München, Germany",11.57756,48.16945,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany",9.185814,48.815163,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Prince of Wales Hospital, Hong Kong, Hong Kong",114.201222,22.378404,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Princess Margaret Hospital, Hong Kong, Hong Kong",114.1338324,22.3415435,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Queen Mary Hospital, Hong Kong, Hong Kong",114.1312557,22.2701076,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"UOC Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, Italy",9.638066,45.686107,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"ASST degli Spedali Civili di Brescia, Brescia, Italy",10.233707,45.5614101,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy",10.0523058,45.1300126,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy",9.2659593,45.5050198,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Dipartimento di Malattie Infettive, Malattie Infettive I- Malattie Infettive III, AssT Fatebenefratelli Sacco Ospedale Luigi Sacco, Milano, Italy",9.1230078,45.5192174,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy",9.197922,45.4588868,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"UOC Medicina Di Laboratorio, Azienda Ospedaliera di Padova, Padova PD, Italy",11.8880771,45.4015071,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Azienda Ospedaliero Universitaria di Parma, Parma, Italy",10.3083481,44.8016341,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"UOC Malattie Infettive I, Fondazione IRCCS Policlinio San Matteo, Pavia, Italy",9.1488319,45.1962179,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy",9.680999,45.0551613,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy",12.4564793,41.866501,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy",7.6596554,45.0889028,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Yokohama Municipal Citizen's Hospital, Kanagawa, Japan",139.604878,35.4688457,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Nagoya City East Medical Center, Nagoya, Japan",136.9436445,35.1738983,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan",139.818798,35.6946101,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kyungpook National University Hospital, Daegu, Korea, Republic of",128.6051356,35.865942,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Seoul Medical Center, Seoul, Korea, Republic of",127.0981666,37.6127725,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"National Medical Center, Seoul, Korea, Republic of",127.0056589,37.5672412,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands",4.9592096,52.2938961,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Leiden University Medical Center, Leiden, Netherlands",4.4785036,52.1660315,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Erasmus Medical Centre, Rotterdam, Netherlands",4.4678541,51.9108848,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"National University Hospital, Singapore, Singapore",103.7831756,1.2937278,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Singapore General Hospital, Singapore, Singapore",103.8348123,1.2804242,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore",103.8472413,1.3221188,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain",-3.3475567,40.5093672,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Complejo Hospitalario Universitario A Coruña, A Coruña, Spain",-8.3879435,43.3444418,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hospital Universitari Vall d'Hebron, Barcelona, Spain",2.142488,41.4283018,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hospital Universitari de Bellvitge, Barcelona, Spain",2.1042573,41.3448959,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hospital Clinic de Barcelona, Barcelona, Spain",2.1523119,41.3894436,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hospital Universitario Cruces, Bizkaia, Spain",-2.983914,43.2820309,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hospital Universitario Ramón y Cajal, Madrid, Spain",-3.6951156,40.4876043,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain",-3.7190495,40.4389953,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hospital Universitario 12 de Octubre, Madrid, Spain",-3.6990068,40.3760381,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hospital Universitario La Paz, Madrid, Spain",-3.6873977,40.4811633,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hospital Regional Universitario de Málaga, Málaga, Spain",-4.4498416,36.7231736,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hospital Universitario Virgen del Rocio, Sevilla, Spain",-5.9803696,37.3618418,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden",11.9614318,57.6823672,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"SUS (Skanes University Hospital), Malmo, Sweden",13.0016352,55.589568,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Karolinska University Hospital, Stockholm, Sweden",18.030376,59.3482904,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hopitaux Universitaires de Genève, Genève 14, Switzerland",6.1490487,46.1933147,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Ospedale Regionale di Locarno La Carità, Lugano, Switzerland",8.7908616,46.1688293,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Universitätsspital Zürich, Zürich, Switzerland",8.5491775,47.3766158,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan",120.3223407,22.6796829,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"China Medical University Hospital, Taichung, Taiwan",120.6804919,24.1572247,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"National Taiwan University Hospital, Taipei City, Taiwan",121.5189863,25.0407391,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Imperial College Healthcare NHS Trust, London, Greater London, United Kingdom",-0.1743487,51.5178108,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Royal Infirmary of Edinburgh, Edinburgh, United Kingdom",-3.1357575,55.9215065,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Queen Elizabeth University Hospital, Glasgow, United Kingdom",-4.3402152,55.8628356,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom",-0.3582799,53.7442203,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Royal Lancaster Hospital, Lancaster, United Kingdom",-2.7995125,54.0423015,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Liverpool University Hospital, Liverpool, United Kingdom",-2.9641248,53.4093831,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Northwick Park Hospital, London, United Kingdom",-0.3195181,51.5751501,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Royal Free London NHS Foundation Trust, London, United Kingdom",-0.165596,51.553237,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"King's College Hospital NHS Trust, London, United Kingdom",-0.0938548,51.4681404,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"University College London, London, United Kingdom",-0.1340401,51.5245592,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Manchester University NHS Foundation Trust, Manchester, United Kingdom",-2.2277393,53.4607569,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Manchester University NHS Foundation Trust, Manchester, United Kingdom",-2.2277393,53.4607569,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom",-2.2294865,53.5178824,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Derriford Hospital, Plymouth, United Kingdom",-4.116408,50.4166994,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),NCT04292899,"Sheffield Teaching Hospitals, Sheffield, United Kingdom",-1.4923035,53.379171,Remdesivir
A Trial of Remdesivir in Adults With Mild and Moderate COVID-19,NCT04252664,"Jin Yin-tan hospital, Wuhan, Hubei, China",114.2868443,30.6668794,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States",-117.8441325,33.8520823,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Alta Bates Summit Medical Center, Berkeley, California, United States",-122.2688043,37.8642168,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Mills-Peninsula Medical Center, Burlingame, California, United States",-122.3824274,37.5923049,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Eden Medical Center, Castro Valley, California, United States",-122.0888289,37.6979825,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States",-118.1288238,33.9191479,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States",-117.4323129,34.0723526,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"St Joseph Hospital Eureka, Fortuna, California, United States",-124.1424555,40.7839616,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States",-118.2957816,33.7886375,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States",-118.293899,34.0984583,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States",-118.3750021,34.0383728,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States",-118.5896036,34.1709445,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Mission Hospital Regional Medical Center, Mission Viejo, California, United States",-117.6653709,33.5610031,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Los Angeles Medical Center,27300 Iris Avenue, Moreno Valley, California, United States",-117.186026,33.897404,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"El Camino Hospital, Mountain View, California, United States",-122.0795279,37.3691517,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States",-117.9296357,33.624397,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Oakland Medical Center, Oakland, California, United States",-122.2582441,37.8235196,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States",-117.6086894,34.0324565,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States",-117.86362,33.779675,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Los Angeles Medical Center,13651 Willard Street, Panorama City, California, United States",-118.4302294,34.2189257,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Riverside, California, United States",-117.4694322,33.905076,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States",-121.2495341,38.765635,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Sutter Medical Center Sacramento, Sacramento, California, United States",-121.4694362,38.5713948,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States",-117.0951878,32.7913395,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States",-117.1251884,32.8297116,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Oakland Medical Center, 1200 El Camino Real, San Francisco, California, United States",-122.4385597,37.6587814,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States",-122.432128,37.7905249,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Oakland Medical Center, 2425 Geary Blvd, San Francisco, California, United States",-122.4429971,37.7824144,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Oakland Medical Center, 250 Hospital Parkway, Suite 850, San Jose, California, United States",-121.8002512,37.2398041,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Oakland Medical Center, 2500 Merced St, San Leandro, California, United States",-122.1647052,37.7064867,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Oakland Medical Center, 700 Lawrence Expressway, Santa Clara, California, United States",-121.9988333,37.3360472,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Providence St. Johns Medical Center, Santa Monica, California, United States",-118.4796445,34.0307739,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States",-122.7510442,38.4952463,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Stanford Hospital, Stanford, California, United States",-122.1758669,37.4347593,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States",-104.8375727,39.7452818,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States",-104.9715971,39.7464498,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"SCL Health St. Joseph Hospital, Denver, Colorado, United States",-104.9715971,39.7464498,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Rose Medical Center, Denver, Colorado, United States",-104.9335815,39.7319823,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States",-105.086874,39.9699702,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Yale University, New Haven, Connecticut, United States",-72.9223431,41.3163244,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States",-157.9000128,21.3632544,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Cook County General Hospital, Chicago, Illinois, United States",-87.67369,41.8728476,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Rush University Medical Center, Chicago, Illinois, United States",-87.6674637,41.8747917,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"University of Chicago, Chicago, Illinois, United States",-87.5987133,41.7886079,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"IU Health Methodist Hospital, Indianapolis, Indiana, United States",-86.1633559,39.7903409,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States",-91.547979,41.658974,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Tulane University, New Orleans, Louisiana, United States",-90.1203167,29.9407282,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Maine Medical Center, Portland, Maine, United States",-70.276399,43.6531739,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Holy Cross Hospital, Silver Spring, Maryland, United States",-77.0347487,39.0147079,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Tufts Medical Center, Boston, Massachusetts, United States",-71.0627826,42.3495371,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States",-71.1074884,42.3361091,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",-71.1049051,42.3397365,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States",-83.7278795,42.283286,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Henry Ford Health System, Detroit, Michigan, United States",-83.0758102,42.3635022,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hennepin Healthcare, Minneapolis, Minnesota, United States",-93.2615378,44.9722477,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Mayo Clinic, Rochester, Minnesota, United States",-92.4668833,44.0226255,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States",-114.0000297,46.8755594,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States",-72.2729872,43.675364,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hackensack Medical Center, Hackensack, New Jersey, United States",-74.0564882,40.8840343,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States",-74.5952861,40.5683581,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States",-74.450131,40.4952121,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States",-74.2125193,40.7100492,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"St. Joseph's University Medical Center, Paterson, New Jersey, United States",-74.1653704,40.9028953,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Jacobi Medical Center, Bronx, New York, United States",-73.8463639,40.855993,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"James J. Peters Veterans Administration Medical Center, Bronx, New York, United States",-73.9064045,40.8674032,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Jamaica Hospital Medical Center, Jamaica, New York, United States",-73.8166244,40.7003783,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Danbury Hospital, Lagrangeville, New York, United States",-73.4451577,41.4054443,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"North Shore University Hospital, Manhasset, New York, United States",-73.7013309,40.7752276,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"North Shore University Hospital, 270-05 76th Ave, New Hyde Park, New York, United States",-73.7073828,40.7543773,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States",-73.9533616,40.7898695,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States",-73.9533616,40.7898695,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States",-73.9533616,40.7898695,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Icahn School of Medicine at Mount Sinai, New York, New York, United States",-73.9533616,40.7898695,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Columbia University Irving Medical Center, New York, New York, United States",-73.941459,40.8409549,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Weill Cornell Medical College/NYU Presbyterian Hospital, New York, New York, United States",-73.9542869,40.7643076,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Duke University Medical Center, Durham, North Carolina, United States",-78.9371331,36.0058487,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",-81.6060645,41.5052505,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States",-122.8767439,45.5394714,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Providence Portland Medical Center, Portland, Oregon, United States",-122.6127272,45.5275562,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Providence St. Vincent Medical Center, Portland, Oregon, United States",-122.771627,45.5104546,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaiser Sunnyside Medical Center, Portland, Oregon, United States",-122.5601232,45.4314461,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States",-75.1938829,39.9501477,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",-75.1938829,39.9501477,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Temple University Hospital, Philadelphia, Pennsylvania, United States",-75.1507582,40.0050435,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"The Miriam Hospital, Providence, Rhode Island, United States",-71.398257,41.851722,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Prisma Health Richland Hospital, Columbia, South Carolina, United States",-81.0333789,34.0279493,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Prisma Health Richland Hospital, 701 Grove Road, Greenville, South Carolina, United States",-82.4109998,34.818455,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States",-96.82346,32.7608903,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States",-96.8350262,32.8086365,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Baylor University Medical Center, Dallas, Texas, United States",-96.779048,32.7896805,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States",-96.8350262,32.8086365,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States",-96.8419366,32.8173287,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States",-97.345412,32.7296877,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Houston Methodist Hospital, Houston, Texas, United States",-95.399568,29.7106626,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States",-97.3640532,31.0779405,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"University of Utah Health, Salt Lake City, Utah, United States",-111.8366784,40.7715716,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Virginia Hospital Center, Arlington, Virginia, United States",-77.127521,38.8891114,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Inova Fairfax Hospital, Falls Church, Virginia, United States",-77.2281251,38.8573966,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"VCU Health Medical Center, Richmond, Virginia, United States",-77.4299508,37.5408047,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Providence Medical Research Center, Everett, Washington, United States",-122.2052146,48.0000596,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kadlec Regional Medical Center, Kennewick, Washington, United States",-119.2822234,46.2813864,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Providence St. Peter Hospital, Olympia, Washington, United States",-122.8479904,47.0529957,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Virginia Mason Medical Center, Seattle, Washington, United States",-122.3277093,47.6099974,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Swedish Center for Comprehensive Care, Seattle, Washington, United States",-122.3214872,47.6063315,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"MultiCare Deaconess Hospital, Spokane, Washington, United States",-117.4235336,47.6517794,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"MultiCare Tacoma General Hospital, Tacoma, Washington, United States",-122.4529736,47.2593705,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"St Joseph Medical Center, Tacoma, Washington, United States",-122.4478581,47.2453583,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China",113.261861,23.113169,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"CHU Pellegrin, Bordeaux, France",-0.6043875,44.8274249,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"CHU de Montpellier-Hopital Gui de Chauliac, Montpelier Cedex 5, France",3.8623414,43.6301844,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"CHU de Nantes-Hotel Dieu, Nantes, France",-1.5545498,47.2107575,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hopital Saint-Louis, Paris, France",2.3672856,48.8771612,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hopital Saint Antoine, Paris, France",2.3827263,48.8488116,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany",13.3766245,52.5264618,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Germany",6.7922861,51.195064,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany",9.974533,53.5908116,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany",10.1433156,54.3307016,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany",12.375768,51.385368,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany",11.599781,48.137976,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Klinik für Hämatologie, Onkologie, Immunologie, München, Germany",11.57756,48.16945,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany",9.185814,48.815163,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Prince of Wales Hospital, Hong Kong, Hong Kong",114.201222,22.378404,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Princess Margaret Hospital, Hong Kong, Hong Kong",114.1338324,22.3415435,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Queen Mary Hospital, Hong Kong, Hong Kong",114.1312557,22.2701076,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"UOC Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, Italy",9.638066,45.686107,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"ASST degli Spedali Civili di Brescia, Brescia, Italy",10.233707,45.5614101,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy",10.0523058,45.1300126,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy",9.2659593,45.5050198,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"ASST Fatebenefratelli Sacco, Milano, Italy",9.2190716,45.4847912,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy",9.197922,45.4588868,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"UOC Malattie Infettive e Tropicali, Azienda Ospedaliera di Padova, Padova PD, Italy",11.8909972,45.4042074,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Azienda Ospedaliero Universitaria di Parma, Parma, Italy",10.3083481,44.8016341,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Malattie Infettive I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy",9.1488319,45.1962179,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy",9.680999,45.0551613,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy",12.4564793,41.866501,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy",7.6596554,45.0889028,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Yokohama Municipal Citizen's Hospital, Kanagawa, Japan",139.604878,35.4688457,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Nagoya City East Medical Center, Nagoya, Japan",136.9436445,35.1738983,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan",139.818798,35.6946101,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kyungpook National University Hospital, Daegu, Korea, Republic of",128.6051356,35.865942,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Seoul Medical Center, Seoul, Korea, Republic of",127.0981666,37.6127725,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"National Medical Center, Seoul, Korea, Republic of",127.0056589,37.5672412,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands",4.9592096,52.2938961,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Leiden University Medical Center, Leiden, Netherlands",4.4785036,52.1660315,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Erasmus Medical Centre, Rotterdam, Netherlands",4.4678541,51.9108848,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"National University Hospital, Singapore, Singapore",103.7831756,1.2937278,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Singapore General Hospital, Singapore, Singapore",103.8348123,1.2804242,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore",103.8472413,1.3221188,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain",-3.3475567,40.5093672,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Complejo Hospitalario Universitario A Coruña, A Coruña, Spain",-8.3879435,43.3444418,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hospital Universitario Vall d'Hebron, Barcelona, Spain",2.142488,41.4283018,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hospital Universitari de Bellvitge, Barcelona, Spain",2.1042573,41.3448959,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hospital Clinic de Barcelona, Barcelona, Spain",2.1523119,41.3894436,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hospital Universitario Cruces, Bizkaia, Spain",-2.983914,43.2820309,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hospital Universitario Ramón y Cajal, Madrid, Spain",-3.6951156,40.4876043,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain",-3.7190495,40.4389953,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hospital Universitario 12 de Octubre, Madrid, Spain",-3.6990068,40.3760381,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hospital Universitario La Paz, Madrid, Spain",-3.6873977,40.4811633,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hospital Regional Universitario de Málaga, Málaga, Spain",-4.4498416,36.7231736,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hospital Universitario Virgen del Rocio, Sevilla, Spain",-5.9803696,37.3618418,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hospital Universitari i Politecnic La Fe, Valencia, Spain",-0.3762115,39.44351,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden",11.9614318,57.6823672,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"SUS (Skanes University Hospital), Malmo, Sweden",13.0016352,55.589568,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Karolinska University Hospital, Stockholm, Sweden",18.030376,59.3482904,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hopitaux Universitaires de Genève, Genève 14, Switzerland",6.1490487,46.1933147,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Ospedale Regionale di Locarno La Carità, Lugano, Switzerland",8.7908616,46.1688293,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Universitätsspital Zürich, Zürich, Switzerland",8.5491775,47.3766158,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan",120.3223407,22.6796829,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"China Medical University Hospital, Taichung, Taiwan",120.6804919,24.1572247,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"National Taiwan University Hospital, Taipei City, Taiwan",121.5189863,25.0407391,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Imperial College NHS Trust, London, Greater London, United Kingdom",-0.1743487,51.5178108,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"NHS Lothian, Royal lnfirmary of Edinburgh, Edinburgh, United Kingdom",-3.1357575,55.9215065,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Queen Elizabeth University Hospital, Glasgow, United Kingdom",-4.3402152,55.8628356,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom",-0.3582799,53.7442203,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Royal Lancaster Hospital, Lancaster, United Kingdom",-2.7995125,54.0423015,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Liverpool University Hospital, Liverpool, United Kingdom",-2.9641248,53.4093831,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Northwick Park Hospital, London, United Kingdom",-0.3195181,51.5751501,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Royal Free London NHS Foundation Trust, London, United Kingdom",-0.165596,51.553237,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"King's College Hospital NHS Trust, London, United Kingdom",-0.0938548,51.4681404,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"University College London, London, United Kingdom",-0.1340401,51.5245592,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Manchester University NHS Foundation Trust, Manchester, United Kingdom",-2.2277393,53.4607569,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Manchester University NHS Foundation Trust, Manchester, United Kingdom",-2.2277393,53.4607569,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom",-2.2294865,53.5178824,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Derriford Hospital, Plymouth, United Kingdom",-4.116408,50.4166994,Remdesivir
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,NCT04292730,"Sheffield Teaching Hospitals, Sheffield, United Kingdom",-1.4923035,53.379171,Remdesivir
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,NCT04409262,"eStudySite - Chula Vista - PPDS, Chula Vista, California, United States",-117.024154,32.6172649,Remdesivir
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,NCT04409262,"Ochsner Clinic Foundation, New Orleans, Louisiana, United States",-90.1139717,30.0206297,Remdesivir
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,NCT04409262,"Louisiana State University Health Sciences Center/Ochsner, Shreveport, Louisiana, United States",-93.7608764,32.4807365,Remdesivir
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,NCT04409262,"Boston Medical Center, Boston, Massachusetts, United States",-71.0731311,42.3344959,Remdesivir
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,NCT04409262,"Baystate Medical Center, Springfield, Massachusetts, United States",-72.6037013,42.1216158,Remdesivir
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,NCT04409262,"St. Michael'S Medical Center, Newark, New Jersey, United States",-74.1752203,40.7443458,Remdesivir
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,NCT04409262,"Intermountain LDS Hospital, Salt Lake City, Utah, United States",-111.87937,40.778402,Remdesivir
A Trial of Remdesivir in Adults With Severe COVID-19,NCT04257656,"Bin Cao, Beijing, Beijing, China",116.4231333,39.942654,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"University of Alabama- Birmingham, Birmingham, Alabama, United States",-86.8064433,33.5019893,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Banner- University Medical Center Phoenix, Phoenix, Arizona, United States",-112.0575015,33.4646895,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Community Regional Medical Centers (CRMC), Fresno, California, United States",-119.7848543,36.742835,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"St. Jude Medical Center, Fullerton, California, United States",-117.9272201,33.8943451,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Scripps Memorial Hospital La Jolla, La Jolla, California, United States",-117.2255426,32.8851578,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Long Beach Memorial Medical Center, Long Beach, California, United States",-118.1853042,33.8094612,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Huntington Hospital, Pasadena, California, United States",-118.1521448,34.133943,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Scripps Mercy Hospital, San Diego, California, United States",-117.1605004,32.7515454,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"California Pacific Medical Center, San Francisco, California, United States",-122.4347006,37.7683466,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"University of California, Medical Center (Parnassus Campus), San Francisco, California, United States",-122.4578922,37.7627248,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Regional Medical Center, San Jose, California, United States",-121.8497581,37.36277,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"San Mateo Medical Center, San Mateo, California, United States",-122.3003345,37.5308786,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Santa Rosa Memorial Hospital, Santa Rosa, California, United States",-122.7013876,38.4436202,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Los Robles Regional Medical Center, Thousand Oaks, California, United States",-118.8832649,34.207655,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"PIH Health Whittier Hospital, Whittier, California, United States",-118.0494059,33.9694666,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"The Medical Center Of Aurora, Aurora, Colorado, United States",-104.8319627,39.6901471,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Rose Medical Center, Denver, Colorado, United States",-104.9335815,39.7319823,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Swedish Medical Center, Englewood, Colorado, United States",-104.9805872,39.6538848,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Greenwich Hospital, Greenwich, Connecticut, United States",-73.629904,41.0344748,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Middlesex Health, Middletown, Connecticut, United States",-72.6470639,41.5544714,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"The Hospital of Central Connecticut, New Britain, Connecticut, United States",-72.7867516,41.6613941,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"The Stamford Health Medical Group- Pulmonary Associates, Stamford, Connecticut, United States",-73.5524563,41.0549124,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"George Washington University Hospital, Washington, District of Columbia, United States",-77.0507412,38.901261,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Aventura Hospital and Medical Center, Aventura, Florida, United States",-80.1457302,25.9702499,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Lawnwood Regional Medical Center, Fort Pierce, Florida, United States",-80.345465,27.4318538,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Memorial Regional Hospital, Hollywood, Florida, United States",-80.1800027,26.0198457,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Mayo Clinic in Florida, Jacksonville, Florida, United States",-81.4451456,30.2626481,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Mount Sinai Medical Center, Miami Beach, Florida, United States",-80.1414798,25.8130379,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"AdventHealth Orlando, Investigational Drug Services, Orlando, Florida, United States",-81.3707509,28.5746404,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Sarasota Memorial Hospital, Sarasota, Florida, United States",-82.53174,27.3187202,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Piedmont Atlanta Hospital, Atlanta, Georgia, United States",-84.395574,33.8087433,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Wellstar Atlanta Medical Center, Atlanta, Georgia, United States",-84.3729609,33.7629065,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Piedmont Columbus Regional-Midtown Hospital, Columbus, Georgia, United States",-84.9818414,32.4805568,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Grady Health System- Grady Memorial Hospital, Decatur, Georgia, United States",-84.3820071,33.751785,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Piedmont Fayette Hospital, Fayetteville, Georgia, United States",-84.5081318,33.4527476,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Memorial Health University Medical Center, Savannah, Georgia, United States",-81.088798,32.030295,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"John D. Archbold Memorial Hospital, Thomasville, Georgia, United States",-83.9721278,30.8251693,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Swedish Hospital, Chicago, Illinois, United States",-87.6994788,41.9753719,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Mercy Hospital & Medical Center, Chicago, Illinois, United States",-95.71695,37.2253156,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Northwestern Lake Forest Hospital, Lake Forest, Illinois, United States",-87.865238,42.2553365,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Loyola University Medical Center, Maywood, Illinois, United States",-87.8354513,41.860567,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Northwestern Medicine Central DuPage Hospital, Winfield, Illinois, United States",-88.1562162,41.873256,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"St. Vincent Hospital and Health Care Center, Inc., Carmel, Indiana, United States",-86.1442253,39.9821468,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Richard L Roudebush Indianapolis VA, Indianapolis, Indiana, United States",-86.1867987,39.7781772,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Riverview Health, Noblesville, Indiana, United States",-86.0234347,40.0460751,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Our Lady of the Lakes Regional Medical Center, Baton Rouge, Louisiana, United States",-91.1075419,30.4040862,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Touro Infirmary, New Orleans, Louisiana, United States",-90.0922393,29.9255899,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Ochsner Clinic Foundation, New Orleans, Louisiana, United States",-90.1139717,30.0206297,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Slidell Memorial Hospital, Slidell, Louisiana, United States",-89.7704122,30.2838293,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"University of Maryland, Baltimore, Maryland, United States",-76.6257057,39.2892017,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Mercy Medical Center, Baltimore, Maryland, United States",-76.612734,39.2930847,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Calvert Health Medical Center, Prince Frederick, Maryland, United States",-76.5963089,38.5593911,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"University of Maryland St. Joseph Medical Center, Towson, Maryland, United States",-76.6117609,39.3882915,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Steward St. Elizabeth's Medical Center of Boston, Inc., Boston, Massachusetts, United States",-71.1480227,42.3489047,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Cambridge Health Alliance, Cambridge, Massachusetts, United States",-71.1044036,42.3748656,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Charlton Memorial Hospital, Fall River, Massachusetts, United States",-71.1462713,41.7099524,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Lawrence General Hospital, Lawrence, Massachusetts, United States",-71.1502191,42.709852,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Lowell General Hospital, Lowell, Massachusetts, United States",-71.34085,42.647772,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"South Shore Hospital, South Weymouth, Massachusetts, United States",-70.9541728,42.1757238,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"UMass Memorial Medical Center, Worcester, Massachusetts, United States",-71.7920244,42.2730591,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"St. Joseph Mercy Hospital, Ann Arbor, Michigan, United States",-83.6558552,42.2650021,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Huron Valley-Sinai Hospital, Commerce, Michigan, United States",-83.498856,42.5925502,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Wayne Statue University/ Detroit Receiving Hospital, Detroit, Michigan, United States",-83.0567987,42.3544796,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Henry Ford Health System, Detroit, Michigan, United States",-83.0758102,42.3635022,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"McLaren Health Care Corporation, Flint, Michigan, United States",-83.742242,43.011833,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Bronson Methodist Hospital, Kalamazoo, Michigan, United States",-85.580433,42.2855115,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"University of Mississippi Medical Center, Jackson, Mississippi, United States",-90.1736583,32.3299207,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Washington University School of Medicine, Saint Louis, Missouri, United States",-90.2629289,38.6351441,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"CarePoint Health Bayonne Medical Center, Bayonne, New Jersey, United States",-74.1123729,40.6681687,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Clara Maass Medical Center, Belleville, New Jersey, United States",-74.1764487,40.7856535,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Cooper University Hospital, Camden, New Jersey, United States",-75.1169561,39.9415299,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hackensack Meridian Health - JFK Medical Center, Edison, New Jersey, United States",-74.3504719,40.5563582,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Trinitas Regional Medical Center, Elizabeth, New Jersey, United States",-74.2145035,40.6590205,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Englewood Health, Englewood, New Jersey, United States",-73.9687157,40.9042797,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hunterdon Medical Center, Flemington, New Jersey, United States",-74.86113,40.5314853,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"CentraState Medical Center, Freehold, New Jersey, United States",-74.3109106,40.2386315,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Robert Wood Johnson University Hospital Hamilton, Hamilton, New Jersey, United States",-74.6716971,40.2160069,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Jersey City Medical Center, Jersey City, New Jersey, United States",-74.0510031,40.7155777,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Christ Hospital- Carepoint Health, Jersey City, New Jersey, United States",-74.0501141,40.7341106,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Monmouth Medical Center, Long Branch, New Jersey, United States",-73.9854333,40.2954704,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Atlantic Health System/ Morristown Medical Center, Morristown, New Jersey, United States",-74.4656519,40.7894006,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Jersey Shore University Medical Center, Neptune, New Jersey, United States",-74.0405748,40.2089489,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Saint Peter's University Hospital, New Brunswick, New Jersey, United States",-74.4590954,40.5021227,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Saint Michael's Medical Center, Newark, New Jersey, United States",-74.1752203,40.7443458,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"University Hospital, Newark, New Jersey, United States",-74.1901945,40.7401785,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Ocean Medical Center, Oakhurst, New Jersey, United States",-74.1316667,40.0769444,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Bayshore Medical Center, Red Bank, New Jersey, United States",-74.1917012,40.4054853,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"The Valley Hospital, Ridgewood, New Jersey, United States",-74.1005112,40.9838774,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Atlantic Health System/Overlook Medical Center, Summit, New Jersey, United States",-74.3526072,40.7128985,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Holy Name Medical Center, Teaneck, New Jersey, United States",-74.010588,40.8827798,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Capital Health, Trenton, New Jersey, United States",-74.7520604,40.2359639,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Virtua Health Voorhees Campus, Voorhees, New Jersey, United States",-74.9275257,39.8426668,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"St. Peter's Hospital, Albany, New York, United States",-73.8037182,42.6558325,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Mount Sinai Queens, Astoria, New York, United States",-73.9248154,40.7680385,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Good Samaritan Hospital Medical Center, Bay Shore, New York, United States",-73.2944672,40.6940791,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Southside Hospital, Bay Shore, New York, United States",-73.2415629,40.7258337,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Lincoln Medical Center, Bronx, New York, United States",-73.9243948,40.816972,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"St Barnabus Hospital, Bronx, New York, United States",-73.8913311,40.8529975,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Montefiore Medical Center, Weiler Campus, Bronx, New York, United States",-73.8458397,40.8492061,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Montefiore Health System Moses Medical Center, Bronx, New York, United States",-73.880041,40.8804291,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"The Brooklyn Hospital Center, Brooklyn, New York, United States",-73.9777743,40.691265,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Kingsbrook Jewish Medical Center, Brooklyn, New York, United States",-73.9332436,40.6593818,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"University Hospital Brooklyn (SUNY Downstate), Brooklyn, New York, United States",-73.945734,40.6552459,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Woodhull Medical Center, Brooklyn, New York, United States",-73.9425116,40.6996948,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Kings County Hospital Center, Brooklyn, New York, United States",-73.9439771,40.656587,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"New York Harbor VA Medical Center, Brooklyn, New York, United States",-74.0240443,40.60855,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Brookdale University Hospital and Medical Center, Brooklyn, New York, United States",-73.9123577,40.6549713,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Interfaith Medical Center, Brooklyn, New York, United States",-73.9373439,40.678599,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States",-73.978424,40.6677145,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Maimonides Medical Center, Brooklyn, New York, United States",-73.9982409,40.6393024,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"NYU Langone Hospital - Brooklyn, Brooklyn, New York, United States",-74.0208955,40.6467233,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Mount Sinai Brooklyn, Brooklyn, New York, United States",-73.9428238,40.6187604,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"New York City Health and Hospitals - Coney Island, Brooklyn, New York, United States",-73.9648753,40.5855566,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Kaleida Health System, Buffalo, New York, United States",-78.8648375,42.9011764,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Nassau University Medical Center, East Meadow, New York, United States",-73.554059,40.727212,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"New York Presbyterian- Queens, Flushing, New York, United States",-73.8253356,40.7472479,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Glens Falls Hospital, Glens Falls, New York, United States",-73.6460742,43.3062687,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Queens Hospital Center, Jamaica, New York, United States",-73.8044537,40.7169469,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"NYU Langone Health, New York, New York, United States",-73.9722693,40.746844,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hospital for Special Surgery, New York, New York, United States",-73.952559,40.7650229,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"New York City Health and New York City Health and Hospitals - Metropolitan- Metropolitan, New York, New York, United States",-73.9444135,40.7848328,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"NewYork-Presyterian/Columbia University Irving Medical Center- Milstein Hospital, New York, New York, United States",-73.9430784,40.8414368,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"New York City Health + Hospitals / Harlem, New York, New York, United States",-73.9395087,40.8143104,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"New York Presbyterian Lower Manhattan Hospital, New York, New York, United States",-74.004758,40.7099166,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Memorial Sloan-Kettering Cancer Center, New York, New York, United States",-73.9634264,40.7646529,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Mount Sinai South Nassau, Oceanside, New York, United States",-73.6305987,40.6519366,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Vassar Brothers Medical Center, Poughkeepsie, New York, United States",-73.9357942,41.6943079,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Rochester General Hospital, Rochester, New York, United States",-77.5878398,43.1924948,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"St. Francis Hospital, Roslyn, New York, United States",-73.6702617,40.8046832,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Ellis Hospital, Schenectady, New York, United States",-73.916504,42.8200283,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Staten Island University Hospital- Northwell Health (North Campus), Staten Island, New York, United States",-74.086124,40.5847086,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Stony Brook University Hospital/ Stony Brook Children's, Stony Brook, New York, United States",-73.1162806,40.908827,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Samaritan Hospital, Troy, New York, United States",-73.6726737,42.7340076,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"UNC Hospitals, Chapel Hill, North Carolina, United States",-79.0514592,35.9039805,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Atrium Health- Carolinas Medical Center, Charlotte, North Carolina, United States",-80.8208167,35.2098767,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"MetroHealth Medical Center, Cleveland, Ohio, United States",-81.698272,41.4620817,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"The Ohio State University College of Medicine, Columbus, Ohio, United States",-83.0168242,39.9941487,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Kettering Medical Center, Kettering, Ohio, United States",-84.1910137,39.6975779,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Saint Francis Hospital, Tulsa, Oklahoma, United States",-95.919195,36.072651,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"St. Luke's Hospital - Bethlehem Campus, Bethlehem, Pennsylvania, United States",-75.3937008,40.6089201,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Mercy Catholic Medical Center - Fitzgerald Campus, Darby, Pennsylvania, United States",-75.2685264,39.9271854,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"St Mary Medical Center, Langhorne, Pennsylvania, United States",-74.9252443,40.2026571,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Philadelphia VA Medical Center, Philadelphia, Pennsylvania, United States",-75.2001349,39.9479816,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Einstein Medical Center Philadelphia, Philadelphia, Pennsylvania, United States",-75.1423534,40.0366347,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Allegheny Health Network, Pittsburgh, Pennsylvania, United States",-80.007677,40.4571516,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"UPMC, Pittsburgh, Pennsylvania, United States",-79.9607843,40.4420639,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Roger Williams Medical Center,, Providence, Rhode Island, United States",-71.4355842,41.8346224,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Kent Hospital, Warwick, Rhode Island, United States",-71.477898,41.705411,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"St. Francis Hospital, Greenville, South Carolina, United States",-82.4214367,34.8403716,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Lexington Medical Center, West Columbia, South Carolina, United States",-81.1135067,34.006705,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"TriStar Centennial Medical Center, Nashville, Tennessee, United States",-86.8092799,36.1537953,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"St. David's South Austin Medical Center, Austin, Texas, United States",-97.7746416,30.2253622,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Texas Health Presbyterian Hospital Dallas, Dallas, Texas, United States",-96.7614722,32.8796103,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"HCA Houston Healthcare West, Houston, Texas, United States",-95.5945083,29.7291522,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"University of Texas Medical Branch Galveston, League City, Texas, United States",-95.0429716,29.5080423,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Covenant Medical Center, Lubbock, Texas, United States",-101.8921,33.576903,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Methodist Mansfield Medical Center, Mansfield, Texas, United States",-97.0944701,32.5683689,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Methodist Healthcare System of San Antonio, Ltd. LLP, dha, Methodist Hospital, San Antonio, Texas, United States",-98.572222,29.5078753,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Saint Mark's Hospital, Salt Lake City, Utah, United States",-111.8574151,40.6862543,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Inova Fairfax Medical Campus, Falls Church, Virginia, United States",-77.2281251,38.8573966,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Henrico Doctors Hospital, Richmond, Virginia, United States",-77.540136,37.6042575,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Carilion Medical Center, Roanoke, Virginia, United States",-80.0081915,37.3001642,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Overlake Hospital Medical Center, Bellevue, Washington, United States",-122.1868308,47.6208557,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"University of Washington Medical Center- Montlake Campus, Seattle, Washington, United States",-122.3053296,47.6485967,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Medical College of Wisconsin, Milwaukee, Wisconsin, United States",-88.02212,43.0429926,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia",151.2207522,-33.8805454,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"The Alfred Hospital, Melbourne, Victoria, Australia",144.9819197,-37.8456704,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"The Royal Melbourne Hospital, Parkville, Victoria, Australia",144.95617,-37.7989153,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Universitätsklinik für Innere Medizin II, Innsbruck, Austria",11.4041024,47.2692124,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Kepler Universitätsklinikum, Linz, Austria",14.305467,48.303292,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Sozialmedizinisches Zentrum Süd - Kaiser-Franz-Josef-Spital, Wien, Austria",16.3507732,48.1741674,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Centre Hospitalier Universitaire Saint Pierre, Brussels, Belgium",4.345909,50.8344868,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Ghent University Hospital, Ghent, Belgium",3.7261488,51.0243757,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Jessa Ziekenhuis, Hasselt, Belgium",5.3422505,50.9101853,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"AZ Groeninge, Kortrijk, Belgium",3.2657973,50.8006544,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Universitair Ziekenhuis Leuven, Leuven, Belgium",4.6743355,50.8785917,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Centre Hospitalier Universitaire de Liège, Liège, Belgium",5.5670127,50.5725359,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hôpital Civil Marie Curie, Lodelinsart, Belgium",4.4390186,50.4307688,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"William Osler Health System, Brampton, Ontario, Canada",-79.7616899,43.6688351,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"The Ottowa Hospital, Ottawa, Ontario, Canada",-75.7214357,45.3925787,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Nicosia General Hospital, Nicosia, Cyprus",33.3770175,35.1275993,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Všeobecná fakultní nemocnice v Praze, Prague, Czechia",14.421015,50.0733909,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Eticka komise pro multicentircke klinicke hodnoceni Fakultni nemocnice v Motole, Praha 5, Czechia",14.3426023,50.0737696,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Nemocnice Na Bulovce, Praha 8, Czechia",14.4640562,50.1153757,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Rigshospitalet, Copenhagen, Denmark",12.5667877,55.6960841,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Põhja-Eesti Regionaalhaigla, Tallinn, Estonia",24.7010389,59.3983667,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Vilnius University, Tartu, Estonia",25.2796514,54.6871555,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hopital Avicenne, Bobigny, France",2.4250233,48.9158686,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Centre Hospitalier Regional Universitaire Brest Hôpital de la Cavale Blanche à Brest, Brest Cedex, France",-4.5283949,48.4015109,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Centre Hospitalier Universitaire Gabriel-Montpied, Clermont Ferrand, France",3.0914286,45.7592004,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hôpitaux Civils de Colmar, Colmar, France",7.337097,48.0755629,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Centre Hospitalier Sud Francilien, Corbeil Essonnes, France",2.4563603,48.6205823,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hôpital Raymond Poincaré, Garches, France",2.1706494,48.838653,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Centre Hospitalier Régional d'Orléans, Orléans, France",1.9206942,47.8361644,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Centre Hospitalier Universitaire de Poitiers, Poitiers, France",0.3849052,46.5589271,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hôpital Charles-Nicolle, Rouen, France",1.1070767,49.4409351,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Saint Josef Hospital Ruhr Universitaet Bochum, Bochum, Germany",7.2299565,51.4917894,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany",13.7765193,51.0544932,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Universitatsklinikum, Essen, Germany",6.9890087,51.4364493,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Universitätsklinikum Freiburg, Freiburg, Germany",7.8394874,48.0058642,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Universitätsmedizin Göttingen, Göttingen, Germany",9.9439393,51.5505609,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Medizinische Hochschule Hannover, Hannover, Germany",9.8049569,52.3835661,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Universitätsklinikum Heidelberg, Heidelberg, Germany",8.67066,49.41288,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Universitätsklinikum des Saarlandes, Homburg, Germany",7.3458226,49.3064546,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Caritas-Krankenhaus St. Josef, Regensburg, Germany",12.11875,49.0073861,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Klinikum Würzburg Mitte, Würzburg, Germany",9.953425,49.7943468,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"University General Hospital of Patras Panagia I Voithia, Patra, Greece",21.7950459,38.2945759,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"General Hospital of Thessaloniki George Papanikolaou, Thessaloniki, Greece",23.0448787,40.6310278,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Kenézy Gyula Kórház És Rendelőintézet, Debrecen, Hungary",21.6087213,47.5328052,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Landspítali, Reykjavik, Iceland",-21.9273956,64.1384022,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Kerry University Hospital, Tralee, Ireland",-9.6886432,52.2652569,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Shaare Zedek Medical Center, Jerusalem, Israel",35.185261,31.773199,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hasharon Hospital, Petah Tikva, Israel",34.8817607,32.0791871,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Sheba Medical Center at Tel Hashomer, Ramat Gan, Israel",34.842852,32.04671,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Ancona, Italy",13.4547895,43.6019431,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Azienda Universitaria Ospedaliera Consorziale - Policlinico di Bari, Bari, Italy",16.86185,41.1120624,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Azienda Ospedaliero Universitaria, Bologna, Italy",11.3628626,44.4917102,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Presidio Ospedaliero Garibaldi-Nesima, Catania, Italy",15.0431833,37.5114616,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Azienda Ospedaliero - Universitaria Careggi, Florence, Italy",11.2470215,43.8072546,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Ospedale Policlinico San Martino, Genova, Italy",8.9696536,44.4079103,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Ospedale San Gerardo di Monza, Monza, Italy",9.2586677,45.6024956,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Azienda Ospedaliera dei Colli, Napoli, Italy",14.2207009,40.8677625,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy",10.395631,43.7217638,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Azienda Ospedaliero Universitaria, Turin, Italy",7.6742345,45.0413899,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Radboud Universitair Medisch Centrum, Nijmegen, Netherlands",5.8611812,51.8235728,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"HagaZiekenhuis, The Hague, Netherlands",4.2633732,52.0556288,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Szpital Uniwersytecki w Krakowie, Krakow, Poland",19.9530916,50.0619877,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Wojewódzki Specjalistyczny Szpital im. dr. Wł. Biegańskiego, Lodz, Poland",19.4373736,51.8008301,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Wielospecjalistyczny Szpital Miejski Im Józefa Strusia Zakład Opiekuńczo Leczniczy, Poznan, Poland",16.9307591,52.4062862,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Wojewódzki Szpital Specjalistyczny Megrez Sp. z o.o., Tychy, Poland",19.0076319,50.1138509,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Centro Hospitalar Universitário de Lisboa Central - Hospital Curry Cabral, Lisboa, Portugal",-9.1425133,38.7222155,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Centro Hospitalar Universitário do Porto E.P.E., Porto, Portugal",-8.6195355,41.1472269,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Centro Hospitalar Universitário De São João, Porto, Portugal",-8.6015062,41.1810922,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Institutul National de Boli Infectioase Prof. Dr. Matei Bals, Bucharest, Romania",26.1139908,44.4552889,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Spitalul Clinic de Boli Infecţioase Sfânta Parascheva Iaşi, Iasi, Romania",27.5843775,47.170543,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Clinical hospital for infectious disease, Timisoara, Romania",21.2086793,45.7488716,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Univerzitná Nemocnica L. Pasteura Košice - Pracovisko Rastislavova 43, Košice, Slovakia",21.2554657,48.7078402,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Univerzitetni Klinicni Center Ljubljana, Ljubljana, Slovenia",14.5216619,46.0541576,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Univerzitetni Klinicni Center Maribor, Maribor, Slovenia",15.6487876,46.5517074,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hospital Universitari Germans Trias i Pujol, Badalona, Spain",2.2378635,41.4810618,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hospital General Universitario Gregorio Maranon, Madrid, Spain",-3.6724986,40.4185038,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hospital Universitario Central de Asturias, Oviedo, Spain",-5.8273198,43.3760877,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hospital Universitario Son Espases, Palma de Mallorca, Spain",2.6459085,39.6075129,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hospital Clinico Universitario de Salamanca, Salamanca, Spain",-5.6754372,40.9637872,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hospital Universitario Donostia, San Sebastian, Spain",-1.969499,43.292855,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hospital Virgen De La Salud, Santa Cruz de Tenerife, Spain",-16.2856164,28.4480627,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hospital Virgen De La Salud, Toledo, Spain",-4.0348853,39.8715417,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hospital Clinico Universitario de Valladolid, Valladolid, Spain",-4.7196729,41.6556947,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Hospital Universitario Miguel Servet, Zaragoza, Spain",-0.8999641,41.6339107,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Kantonsspital Aarau, Aarau, Switzerland",8.0600175,47.3890743,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"University Hospital Basel, Basel, Switzerland",7.5830579,47.5621796,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Spitalzentrum Biel, Biel, Switzerland",7.2445793,47.1468069,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Kantonsspital Graubünden, Chur, Switzerland",9.5387292,46.8640364,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Centre Hospitalier Universitaire Vaudois Lausanne, Lausanne, Switzerland",6.6424293,46.5249174,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Luzerner Kantonsspital, Luzern, Switzerland",8.2974611,47.0576832,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"University Hospital of Wales, Cardiff and Vale NHS Trust, Cardiff, United Kingdom",-3.1902577,51.5067958,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Barts Health NHS Trust, London, United Kingdom",-0.0588687,51.5178708,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom",-0.1086417,51.4928419,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"St. George's Hospital, London, United Kingdom",-0.1752284,51.426563,Remdesivir
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),NCT04323761,"Southampton University Hospital, Southampton, United Kingdom",-1.4344979,50.9331825,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States",-86.8039601,33.503198,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States",-117.225354,32.878285,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States",-118.4466758,34.065656,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of California Irvine Medical Center - Infectious Disease, Orange, California, United States",-117.8887236,33.7871702,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States",-122.1402524,37.405063,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States",-122.1743078,37.4379735,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States",-121.4567734,38.5561515,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States",-117.1455806,32.7263636,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States",-122.4050025,37.7561796,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Cedars Sinai Medical Center, West Hollywood, California, United States",-118.3801756,34.075232,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Rocky Mountain Regional Veteran Affairs Medical Center - Department of Infectious Diseases, Aurora, Colorado, United States",-104.8298306,39.7428484,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States",-104.9910801,39.7282404,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine, Gainesville, Florida, United States",-82.3497282,29.6375743,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States",-84.278597,33.790841,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Atlanta VA Medical Center - Infectious Diseases Clinic, Decatur, Georgia, United States",-84.3115191,33.8016027,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States",-87.623185,41.8947452,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States",-87.672656,41.8705427,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases, New Orleans, Louisiana, United States",-90.0846281,29.9613085,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States",-76.625715,39.2889604,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States",-76.5927362,39.2967385,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Walter Reed National Military Medical Center, Bethesda, Maryland, United States",-77.0938454,39.0016164,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States",-77.1043789,39.0025272,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States",-71.0688334,42.3631542,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States",-71.7632542,42.2777464,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States",-93.2311679,44.9711356,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States",-90.231968,38.633482,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States",-95.9759165,41.2548549,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States",-73.8797647,40.8801514,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States",-73.9740737,40.7493378,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States",-77.6269403,43.1230503,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States",-78.9430478,36.0076689,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States",-76.6745953,40.2643934,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of Pennsylvania Perelman School of Medicine - Penn Institute for Immunology, Philadelphia, Pennsylvania, United States",-75.192598,39.9476279,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States",-86.8004882,36.1424588,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of Texas Southwestern Medical Center - Internal Medicine - Infectious Diseases, Dallas, Texas, United States",-96.8451734,32.8157077,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Brooke Army Medical Center, Fort Sam Houston, Texas, United States",-98.4167342,29.4597886,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States",-94.7786557,29.3113831,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States",-95.396499,29.7105296,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States",-98.5753521,29.5074654,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States",-78.5004851,38.0344004,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States",-76.3046348,36.8437973,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States",-122.1786164,47.715878,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Providence Sacred Heart Medical Center, Spokane, Washington, United States",-117.4133073,47.6488744,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States",-122.55207,47.1097586,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan",139.716339,35.7016562,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Korea, Republic of",127.1231772,37.3520673,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Seoul National University Hospital, Seoul, Korea, Republic of",126.9975506,37.5787082,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán - Departamento de Infectologia, Mexico City, Mexico",-99.1553977,19.2891535,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas, Mexico City, Mexico",-99.1590142,19.2921803,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"National University Health System - Division of Infectious Diseases, Singapore, Singapore",103.7835972,1.2922012,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"National Centre for Infectious Diseases (NCID), Singapore, Singapore",103.8472413,1.3221188,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Changi General Hospital - Clinical Trials and Research Unit (CTRU), Singapore, Singapore",103.9495701,1.3401915,Remdesivir
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),NCT04401579,"Ng Teng Fong General Hospital - Infectious Disease Service, Singapore, Singapore",103.7453915,1.3337448,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States",-86.8039601,33.503198,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States",-117.225354,32.878285,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States",-118.4466758,34.065656,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"University of California Irvine Medical Center - Infectious Disease, Orange, California, United States",-117.8887236,33.7871702,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States",-122.1402524,37.405063,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States",-122.1743078,37.4379735,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States",-121.4567734,38.5561515,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States",-117.1455806,32.7263636,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States",-122.4050025,37.7561796,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Cedars Sinai Medical Center, West Hollywood, California, United States",-118.3801756,34.075232,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States",-104.9910801,39.7282404,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States",-84.278597,33.790841,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States",-87.623185,41.8947452,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States",-87.672656,41.8705427,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases, New Orleans, Louisiana, United States",-90.0846281,29.9613085,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Annapolis, Maryland, United States",-76.625715,39.2889604,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States",-76.5927362,39.2967385,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Walter Reed National Military Medical Center, Bethesda, Maryland, United States",-77.0938454,39.0016164,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States",-77.1043789,39.0025272,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States",-71.0688334,42.3631542,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States",-71.7632542,42.2777464,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States",-93.2311679,44.9711356,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States",-90.231968,38.633482,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States",-95.9759165,41.2548549,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States",-73.8797647,40.8801514,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States",-73.9740737,40.7493378,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States",-77.6269403,43.1230503,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States",-78.9430478,36.0076689,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States",-76.6745953,40.2643934,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Hospital of the University of Pennsylvania - Infectious Diseases, Philadelphia, Pennsylvania, United States",-75.1928899,39.9470802,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States",-86.8004882,36.1424588,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Brooke Army Medical Center, Fort Sam Houston, Texas, United States",-98.4167342,29.4597886,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States",-94.7786557,29.3113831,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States",-95.396499,29.7105296,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States",-98.5753521,29.5074654,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States",-78.5004851,38.0344004,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States",-76.3046348,36.8437973,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States",-122.1786164,47.715878,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"The University of Washington - Virology Research Clinic, Seattle, Washington, United States",-122.3182835,47.6588389,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Providence Sacred Heart Medical Center, Spokane, Washington, United States",-117.4133073,47.6488744,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States",-122.55207,47.1097586,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases, Copenhagen, Denmark",12.5667877,55.6960841,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Universitatsklinikum Bonn, Medizinische Klinik I - Bereich Infektiologie/HIV der Medizinischen Klinik, Bonn, Nordrhein-Westfalen, Germany",7.1045497,50.7018469,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Universitatsklinikum Koeln Klinik I fur Innere Medizin Klinisches Studienzentrum fur Infektiologie I, Cologne, Germany",6.9170435,50.9236621,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Universitätsklinikum Frankfurt -Medizinische Klinik II - Infektiologie, Frankfurt, Germany",8.6616969,50.0951726,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"AHEPA University Hospital - 1st Department of Internal Medicine, Thessaloniki, Central Macedonia, Greece",22.9600672,40.629556,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Medical School of Athens University - Evangelismos Hospital - Department of Critical Care and Pulmonary Services, Athens, Greece",23.7786871,37.968196,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan",139.716339,35.7016562,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Gyeonggi-do, Korea, Republic of",127.1231772,37.3520673,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of",126.9975506,37.5787082,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán - Departamento de Infectologia, Mexico City, Mexico",-99.1553977,19.2891535,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas, Mexico City, Mexico",-99.1590142,19.2921803,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"National Centre for Infectious Diseases (NCID), Singapore, Singapore",103.8472413,1.3221188,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Hospital Clinic Barcelona, Servicio de Salud Internacional, Barcelona, Cataluña, Spain",2.1523119,41.3894436,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Hospital Germans Trias i Pujol - Servei Malalties Infeccioses, Barcelona, Cataluña, Spain",2.2378669,41.4811171,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Royal Sussex County Hospital - Department of Intensive Care Medicine, East Sussex, Brighton, United Kingdom",-0.1182958,50.8193472,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Saint Thomas' Hospital - Directorate of Infection, London, London, City Of, United Kingdom",-0.1188545,51.4990946,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"Royal Victoria Infirmary - Department of Infectious Diseases, Level 6, Ward 19, Newcastle Upon Tyne, United Kingdom",-1.6190553,54.9802057,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"St. James's University Hospital - Infectious Diseases, Leeds, West Yorkshire, United Kingdom",-1.5192863,53.806748,Remdesivir
Adaptive COVID-19 Treatment Trial (ACTT),NCT04280705,"John Radcliffe Hospital, Headington, Oxford, United Kingdom",-1.2188774,51.764391,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"Peter Lougheed Centre, Calgary, Alberta, Canada",-113.9839451,51.0789832,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"Foothills Medical Centre, Calgary, Alberta, Canada",-114.1334883,51.0652154,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"Rockyview General Hospital, Calgary, Alberta, Canada",-114.0974163,50.9903099,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"South Health Campus, Calgary, Alberta, Canada",-113.9518929,50.8819537,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"University of Alberta Hopsital, Edmonton, Alberta, Canada",-113.5232015,53.5207634,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"Vancouver General Hospital, Vancouver Coastal Health, Univeristy of British Columbia, Vancouver, British Columbia, Canada",-123.0967667,49.2673536,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"St Paul's Hospital, Vancouver, British Columbia, Canada",-123.1280047,49.2806332,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"Island Health - Royal Jubilee Hospital, Victoria, British Columbia, Canada",-123.3279138,48.4327191,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"Island Health - Victoria General Hospital, Victoria, British Columbia, Canada",-123.4330644,48.4665044,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada",-79.7743193,43.2218746,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"St.Joseph's Health Care, London, Ontario, Canada",-81.2548309,43.0009154,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"University Hospital, London, Ontario, Canada",-81.2745418,43.0124531,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"Victoria Hospital, London, Ontario, Canada",-81.22543,42.960029,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada",-75.6478786,45.4007275,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"Hôpital Montfort, Ottawa, Ontario, Canada",-75.6394863,45.4461659,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"The Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada",-75.7214357,45.3925787,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"Queensway Carleton Hospital, Ottawa, Ontario, Canada",-75.8076141,45.3349843,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"North York General Hospital, Toronto, Ontario, Canada",-79.3627441,43.7690968,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",-79.3756596,43.7224812,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"Toronto Western Hospital, Toronto, Ontario, Canada",-79.4052302,43.6534793,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Quebec, Canada",-73.5574486,45.5112735,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"McGill University Health Centre-Glen Site Royal Victoria Hospital, Montréal, Quebec, Canada",-73.6015785,45.4732623,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"CHU de Québec - Université Laval, Québec, Quebec, Canada",-71.2107848,46.8152117,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"Institut Universitaire de Cardiologie et de Pneumologie de Québec- Université Laval, Québec, Quebec, Canada",-71.2977055,46.7790343,Remdesivir
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,NCT04330690,"Centre Intégré Universitaire de Santé et de Services Sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada",-71.880256,45.407037,Remdesivir
The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients,NCT04321616,"Andreas Barratt-Due, Oslo, Norway",10.7293142,59.9221286,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Universitaire Amiens-Picardie, Amiens, France",2.2558589,49.8728114,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Regional Metz-Thionville, Ars-Laquenexy, France",6.2427775,49.0836738,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Régional Universitaire de Besançon, Besançon, France",5.9626178,47.2253089,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France",-0.6061928,44.829016,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"APHP - hôpital Henri-Mondor, Créteil, France",2.4517989,48.7980441,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Universitaire Dijon-Bourgogne, Dijon, France",5.0691471,47.3213803,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Universitaire de Martinique, Fort De France, France",-61.0380384,14.6339646,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"AP-HP Hôpital Bicêtre, Kremlin-Bicêtre, France",2.3522501,48.8105963,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalo-Universitaire de Grenoble, La Tronche, France",5.741472,45.202285,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Régional Universitaire de Lille, Lille, France",3.0347031,50.6108999,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Hospices Civils de Lyon, Lyon, France",4.8315594,45.7608649,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Universitaire de Montpellier, Montpellier, France",3.8504425,43.6315886,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Groupe Hospitalier de la Région de Mulhouse Sud Alsace, Mulhouse, France",7.3412062,47.7387331,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Régional et Universitaire de Nancy, Nancy, France",6.192022,48.6852009,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Universitaire de Nantes, Nantes, France",-1.5543918,47.2120313,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalo-Universitaire de Nice, Nice, France",7.2822826,43.7243711,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"APHP - Hôpital Saint Antoine, Paris, France",2.3827263,48.8488116,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"APHP - Hôpital Universitaire Pitié Salpêtrière, Paris, France",2.3650429,48.8370792,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"APHP - Hôpital Cochin, Paris, France",2.3402667,48.8368937,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Hôpital Paris Saint-Joseph et Marie Lannelongue, Paris, France",2.3103313,48.829771,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"APHP- Hôpital Européen Georges-Pompidou, Paris, France",2.2740724,48.8389124,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"APHP - Hôpital Bichat Claude Bernard, Paris, France",2.3317094,48.8988449,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Universitaire de Rennes, Rennes, France",-1.6950482,48.1200595,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Hopital DELAFONTAINE, Saint-Denis, France",2.3711375,48.9335315,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Hôpital d'Instruction des Armées BEGIN, Saint-Mandé, France",2.4253137,48.843381,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Universitaire de Saint Etienne, Saint-Étienne, France",4.3629634,45.4820275,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Régional Universitaire de Strasbourg, Strasbourg, France",7.7071667,48.5929237,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Universitaire de Toulouse, Toulouse, France",1.4369245,43.5995462,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Universitaire de Toulouse, Toulouse, France",1.4369245,43.5995462,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier de Tourcoing, Tourcoing, France",3.1812134,50.743301,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Universitaire de Tours, Tours, France",0.6696853,47.3872732,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Annecy Genevois, Épagny, France",6.1175557,45.9338394,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Centre Hospitalier Luxembourg, Luxembourg, Luxembourg",6.100888,49.618558,Remdesivir
Trial of Treatments for COVID-19 in Hospitalized Adults,NCT04315948,"Hôpitaux Robert Schuman, Luxembourg, Luxembourg",6.1765466,49.6323792,Remdesivir
Sarilumab for Patients With Moderate COVID-19 Disease,NCT04359901,"VA Boston Healthcare System, Boston, Massachusetts, United States",-71.1099407,42.3272945,Remdesivir
Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial,NCT04405310,"Hospital Nava de Alta Especialidad, Mexico City, Mexico",-99.1285827,19.3244355,Remdesivir
Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial,NCT04405310,"Hospital General de Mexico Dr Eduardo Liceaga, Mexico City, Mexico",-99.1520225,19.4129258,Remdesivir
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Hospital Universitario de Neiva, Neiva, Huila, Colombia",-75.2811942,2.9321351,Remdesivir
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Clínica Reina Sofía, Bogotá, Colombia",-74.0519893,4.7068994,Remdesivir
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Fundacion Cardio Infantil, Bogotá, Colombia",-74.0345157,4.7413984,Remdesivir
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Hospital Universitario San Ignacio, Bogotá, Colombia",-74.0640042,4.6282546,Remdesivir
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Clinica Universitaria Colombia, Bogotá, Colombia",-74.1065512,4.6482242,Remdesivir
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Hospital Universitario Nacional de Colombia, Bogotá, Colombia",-74.0957156,4.6489485,Remdesivir
"Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19",NCT04373044,"Los Angeles County-USC Medical Center, Los Angeles, California, United States",-118.2075585,34.0575334,Remdesivir
"Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19",NCT04373044,"USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States",-118.2048393,34.0613426,Remdesivir
Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study,NCT04365764,"Centre Hospitalier Intercommunal Robert Ballanger, Aulnay-sous-Bois, France",2.523274,48.9545206,Remdesivir
Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study,NCT04365764,"Centre Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France",2.5720537,48.8984523,Remdesivir
Long-term Use of Drugs That Could Prevent the Risk of Serious COVID-19 Infections or Make it Worse,NCT04356417,"Assistance Publique Hôpitaux de Paris - CHU Henri Mondor, Créteil, France",2.4517989,48.7980441,Remdesivir
Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab,NCT04359667,"University Hospital for Infectious Diseases ""Dr Fran Mihaljevic"", Zagreb, Croatia",15.9801721,45.8297653,Remdesivir
Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19,NCT04386447,"CNRS, Lyon, France",4.8748526,45.7803551,Remdesivir
Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19,NCT04386447,"Azienda Ospedaliero Universitaria di Parma, Parma, PR, Italy",10.3083481,44.8016341,Remdesivir
Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19,NCT04386447,"Ospedale San Francesco, Nuoro, Italy",9.3159735,40.3255781,Remdesivir
Convalescent Plasma Therapy in Severe COVID-19 Infection,NCT04403477,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",90.3946767,23.739822,Remdesivir
Convalescent Plasma Compared to Anti-COVID-19 Human Immunoglobulin and Standard Treatment (TE) in Hospitalized Patients,NCT04395170,"LifeFactors Zona Franca SAS, Medellín, Antioquia, Colombia",-75.4162634,6.1571707,Remdesivir
Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19),NCT04361461,"Apsen Farmacêutica S.A., São Paulo, Brazil",-46.7104346,-23.6477874,Remdesivir
Early Short Course Corticosteroids in COVID-19,NCT04374071,"Henry Ford Hospital, Detroit, Michigan, United States",-83.0854662,42.3678016,Remdesivir
The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol,NCT04349410,"FHHI-OI-Camelot; QME, Los Angeles, California, United States",-118.4595285,34.0501689,Remdesivir
Study of Open Label Losartan in COVID-19,NCT04335123,"University of Kansas Medical Center, Kansas City, Kansas, United States",-94.6113987,39.05635,Remdesivir
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,NCT04334460,"Blade Research Site, Irvine, California, United States",-117.8460245,33.6792494,Remdesivir
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,NCT04334460,"Blade Research Site, Los Angeles, California, United States",-118.318032,34.175903,Remdesivir
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,NCT04334460,"Blade Reseach Site, San Jose, California, United States",-121.8069487,37.211053,Remdesivir
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,NCT04334460,"Blade Research Site, Washington, District of Columbia, United States",-77.0368707,38.9071923,Remdesivir
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,NCT04334460,"Blade Research Site, Tampa, Florida, United States",-82.4907926,27.937781,Remdesivir
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,NCT04334460,"Blade Research Site, Peoria, Illinois, United States",-89.6145301,40.7097557,Remdesivir
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,NCT04334460,"Blade Research Site, Metairie, Louisiana, United States",-90.1528519,29.9840922,Remdesivir
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,NCT04334460,"Blade Research Site, Baltimore, Maryland, United States",-76.5980261,39.2001672,Remdesivir
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,NCT04334460,"Blade Research Site, Detroit, Michigan, United States",-83.0457538,42.331427,Remdesivir
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,NCT04334460,"Blade Research Site, Saint Louis, Missouri, United States",-90.1994042,38.6270025,Remdesivir
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,NCT04334460,"Blade Research Site, North Las Vegas, Nevada, United States",-115.1499011,36.2093572,Remdesivir
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,NCT04334460,"Blade Research Site, Durham, North Carolina, United States",-78.8662219,35.923193,Remdesivir
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,NCT04334460,"Blade Research Site, Fayetteville, North Carolina, United States",-78.8783585,35.0526641,Remdesivir
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,NCT04334460,"Blade Research Site, Philadelphia, Pennsylvania, United States",-75.1652215,39.9525839,Remdesivir
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,NCT04334460,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",-86.8014009,36.1425227,Remdesivir
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"Azienda Ospedaliera ""SS. Antonio e Biagio e C. Arrigo"" (Dipartimento Internistico SSD Reumatologia), Alessandria, Italy",8.6116796,44.9072727,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"Ospedale di Busto Arsizio ASST Valle Olona (U.O.C. Malattie Infettive), Busto Arsizio, Italy",8.846697,45.6219651,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"A.O.U. Policlinico V. Emanuele (U.O. di Malattie infettive, U.O. di Anestesia e Rianimazione, U.O. di Medicina d'Urgenza), Catania, Italy",15.0830304,37.5078772,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"AOE Cannizzaro di Catania (U.O. di Malattie Infettive, U.O. di Anestesia e Rianimazione, U.O., Catania, Italy",15.0830304,37.5078772,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"Ospedale Annunziata Azienda Ospedaliera di Cosenza (U.O.C. Malattie Infettive), Cosenza, Italy",16.2486644,39.293416,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"ASST OVEST MILANESE presidi Legnano - Magenta, Magenta, Italy",8.9319865,45.5952076,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"Azienda Ospedaliero-Universitaria di Modena, Modena, Italy",10.9421901,44.6363441,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione I), Modena, Italy",10.9421901,44.6363441,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione II), Modena, Italy",10.9421901,44.6363441,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"A.O.U. di Modena (Dipartimento Medicine Specialistiche - Struttura Complessa Malattie Infettive), Modena, Italy",10.9421901,44.6363441,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"Dipartimento Medicine Specialistiche - Struttura Complessa Malattie dell'Apparato Respiratorio, Modena, Italy",10.9252269,44.647128,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Oncologia), Naples, Italy",14.2096027,40.8706618,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"National Cancer Institute, Naples, Italy",14.222673,40.8624762,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Anestesia Rianimazione e terapia intensiva), Naples, Italy",14.2096027,40.8706618,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Malattie Infettive ad indirizzo respiratorio), Naples, Italy",14.2096027,40.8706618,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"A.O. Ospedali Riuniti Marche Nord - Presidio Ospedaliero San Salvatore di Pesaro (UOC Pronto Soccorso e Medicina d'Urgenza), Pesaro, Italy",12.9070597,43.9074642,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"Denominazione: UOC di Medicina e Chirurgia d'Accettazione e d'Urgenza dell'Ospedale Santa Maria delle Grazie di Pozzuoli, Pozzuoli, Italy",14.0733013,40.849415,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"Ospedale Santa Maria delle Croci, AUSL della Romagna (U.O. Anestesia e Rianimazione), Ravenna, Italy",12.1902021,44.4100508,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"Grande Ospedale Metropolitano, Reggio Calabria, Reggio Calabria, Italy",15.6594798,38.1130568,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"Ospedale Infermi, AUSL della Romagna (U.O. Malattie Infettive), Rimini, Italy",12.5889668,44.0474034,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"Policlinico Gemelli (U.O.C. Dipartimento Scienze di Laboratorio e Infettivologiche), Rome, Italy",12.4285757,41.9319404,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"ASST Sette Laghi (Dipartimento di Medicina Interna), Varese, Italy",8.8412594,45.8074471,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"ASST Sette Laghi (Dipartimento Emergenze ed Urgenze), Varese, Italy",8.8412594,45.8074471,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"ASST Sette Laghi (U.O.C. Anestesia e Rianimazione Neurochirurgica e Generale), Varese, Italy",8.8412594,45.8074471,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"ASST Sette Laghi (U.O.C. Malattie Infettive e Tropicali), Varese, Italy",8.8412594,45.8074471,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"A.O.U. Integrata di Verona (Dip. Malattie Infettive), Verona, Italy",10.9856288,45.4521332,Tocilizumab
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),NCT04317092,"Ospedale Magalini (U.O. Malattie Infettive), Villafranca Di Verona, Italy",10.8394968,45.3474616,Tocilizumab
Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression,NCT04345445,"University Malaya Medical Centre, Kuala Lumpur, Malaysia",101.6528322,3.1137086,Tocilizumab
"Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis",NCT04331795,"University of Chicago Medicine, Chicago, Illinois, United States",-87.6042591,41.7887967,Tocilizumab
A RCT - Safety & Efficacy of Tocilizumab - Tx of Severe COVID-19: ARCHITECTS,NCT04412772,"Queen's Medical Center, Honolulu, Hawaii, United States",-157.8538531,21.3085481,Tocilizumab
The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,NCT04377750,"Hadassah Medical Orginisation, Jerusalem, Please Select:, Israel",35.1494106,31.7649503,Tocilizumab
The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,NCT04377750,"Barzilai Medical Center, Ashkelon, Israel",34.5592871,31.6622785,Tocilizumab
The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,NCT04377750,"Wolfson Medical Center, H̱olon, Israel",34.7627074,32.0360309,Tocilizumab
The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,NCT04377750,"Sheba Medical Center, Ramat Gan, Israel",34.842852,32.04671,Tocilizumab
"Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia",NCT04361032,"Eshmoun Clinical Research Centre/ Hôpital Abderrahmane Mami-Ariana, Ariana, Tunisia",10.1782429,36.8698022,Tocilizumab
Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab,NCT04359667,"University Hospital for Infectious Diseases ""Dr Fran Mihaljevic"", Zagreb, Croatia",15.9801721,45.8297653,Tocilizumab
"Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19",NCT04332094,"Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",2.174314,41.4136997,Tocilizumab
Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection,NCT04377659,"Memorial Sloan Kettering Cancer Center, New York, New York, United States",-73.9634264,40.7646529,Tocilizumab
"An Open Randomized Therapeutic Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease",NCT04424056,"Assistance Publique Hôpitaux de Marseille, Marseille, France",5.3938612,43.2910081,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"Ospedale di Guastalla, Guastalla, RE, Italy",10.6672675,44.919041,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, RE, Italy",10.4497879,44.7060814,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy",8.6214506,44.9152712,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"Policlinico Sant'Orsola Malpighi, Bologna, Italy",11.3604497,44.4927201,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"ASST Cremona, Cremona, Italy",10.0523058,45.1300126,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy",7.5366136,44.3853584,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"Azienda Ospedaliero Universitaria Ferrara, Ferrara, Italy",11.6963026,44.7998971,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"Azienda Ospedaliero Universitaria Careggi, Firenze, Italy",11.2476977,43.8072701,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"Ospedale Evangelico Internazionale di Genova, Genova, Italy",8.9429838,44.414108,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"Azienda Sociosanitaria ASL 1 ,Imperia, Imperia, Italy",8.0119012,43.8802392,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"Azienda Sociosanitaria ASL 5 La Spezia, La Spezia, Italy",9.8320678,44.1118233,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"ASST Mantova - Ospedale Carlo Poma, Mantova, Italy",10.7732402,45.1448334,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"IRCCS Istituto Auxologico Italiano Milano, Milano, Italy",9.145011,45.471875,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"Azienda Ospedaliero-Universitaria ""Maggiore della Carità"" di Novara, Novara, Italy",8.621987,45.4420038,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"Ospedali Riuniti Padova Sud - ULSS 6 Euganea, Padova, Italy",11.8846965,45.4127245,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"Azienda Ospedaliero-Universitaria Parma, Parma, Italy",10.3083481,44.8016341,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"Azienda Unità Sanitaria Locale di Piacenza, Piacenza, Italy",9.7000319,45.0570706,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"Azienda Ospedaliera Universitaria Pisana, Pisa, Italy",10.4432297,43.7064336,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"AO Ordine Mauriziano di Torino, Torino, Italy",7.6649541,45.0524366,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"ASST Bergamo Ovest -Treviglio, Treviglio, Italy",9.6111994,45.5101004,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"AULSS 2 Marca Trevigiana, Treviso, Italy",12.2644188,45.6612591,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"AULSS2 Marca Trevigiana - Ospedale Vittorio Veneto, Treviso, Italy",12.3197938,45.9873685,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"AULSS 3 Serenissima Ospedale ""Dell'Angelo"", Venezia, Italy",12.2232083,45.513721,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy",10.9856288,45.4521332,Tocilizumab
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,NCT04346355,"IRCCS Sacro Cuore Don Calabria, Verona, Italy",10.9359529,45.5303486,Tocilizumab
Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19),NCT04335071,"University Hospital Bern (Inselspital), Bern, Switzerland",7.4247343,46.9472676,Tocilizumab
Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19),NCT04335071,"Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland",6.6424293,46.5249174,Tocilizumab
Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19),NCT04335071,"Ospedale Regionale di Lugano (EOC), Viganello, Switzerland",8.9606,46.0098198,Tocilizumab
Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19),NCT04335071,"University Hospital Zurich, Zurich, Switzerland",8.5491775,47.3766158,Tocilizumab
"A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study",NCT04412291,"Karolinska University Hospital, Huddinge, Stockholm, Sweden",18.030376,59.3482904,Tocilizumab
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,NCT04403685,"UNIFESP, São Paulo, Sao Paulo, Brazil",-46.6489943,-23.5916438,Tocilizumab
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,NCT04403685,"HCOR -Hospital do Coracao, Sao Paulo, SP, Brazil",-46.6436478,-23.5729864,Tocilizumab
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,NCT04403685,"HAOC - Hospital Alemao Oswaldo Cruz, Sao Paulo, Brazil",-46.6435635,-23.5690595,Tocilizumab
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,NCT04403685,"Beneficência Portuguesa de Sao Paulo, Sao Paulo, Brazil",-46.6419505,-23.5664177,Tocilizumab
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,NCT04403685,"HAOC - Hospital Alemao Oswaldo Cruz - unidade Vergueiro, Sao Paulo, Brazil",-46.638029,-23.562,Tocilizumab
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,NCT04403685,"HIAE - Hospital Israelita Albert Einstein, Sao Paulo, Brazil",-46.7152547,-23.5999606,Tocilizumab
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,NCT04403685,"HSL - Hospital Sírio Libanês, Sao Paulo, Brazil",-46.6537114,-23.5572749,Tocilizumab
Efficacy of Tocilizumab on Patients With COVID-19,NCT04356937,"Massachusetts General Hospital, Boston, Massachusetts, United States",-71.067566,42.3626109,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Banner - University Medical Center Phoenix; In-Patient Pharmacy, Phoenix, Arizona, United States",-112.0575015,33.4646895,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Univ of AZ Coll of Med, Tucson, Arizona, United States",-110.9461054,32.2410865,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Scripps Mercy Hospital, Chula Vista, California, United States",-117.083637,32.633558,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"El Centro Regional Medical Center, El Centro, California, United States",-115.5684684,32.7802257,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"eStudySite, La Mesa, California, United States",-117.0094774,32.7804422,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Riverside University Health System-Medical Center, Moreno Valley, California, United States",-117.1960044,33.9121778,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Highland Hospital Oakland, Oakland, California, United States",-122.2321344,37.7989017,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"San Leandro Hospital; Inpatient Pharmacy, San Leandro, California, United States",-122.1428781,37.7127151,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Yale University School Of Medicine, New Haven, Connecticut, United States",-72.9338698,41.30323,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Howard University, Washington, District of Columbia, United States",-77.0204624,38.9212171,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Westchester General Hospital, Miami, Florida, United States",-80.3176547,25.747314,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Columbus Regional Research Institute, Columbus, Georgia, United States",-84.9600928,32.5268217,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Uni of Kansas Medical Center, Kansas City, Kansas, United States",-94.6113987,39.05635,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Ochsner Clinic, New Orleans, Louisiana, United States",-90.1436859,29.9631002,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"LSU-Shreveport, Shreveport, Louisiana, United States",-93.7034604,32.4284824,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Holy Cross Germantown Hospital, Germantown, Maryland, United States",-77.2424097,39.1817574,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Holy Cross Hospital, Silver Spring, Maryland, United States",-77.0347487,39.0147079,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Henry Ford Health System, Detroit, Michigan, United States",-83.0758102,42.3635022,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Optum Health Care, Las Vegas, Nevada, United States",-115.122352,36.114124,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"St. Joseph'S Regional Medical Center, Paterson, New Jersey, United States",-74.1653704,40.9028953,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"San Juan Oncology Associates, Farmington, New Mexico, United States",-108.2160998,36.7265744,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"St. Barnabas Hospital, Bronx, New York, United States",-73.8913311,40.8529975,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Kings County Hospital Center, Brooklyn, New York, United States",-73.9439771,40.656587,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"SUNY Downstate Medical Center., Brooklyn, New York, United States",-73.9456988,40.6552934,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Elmhurst Hospital Center, Elmhurst, New York, United States",-73.8857314,40.7451694,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Flushing Hospital, Flushing, New York, United States",-73.8166076,40.7551189,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Jamaica Hospital Medical Center, Jamaica, New York, United States",-73.8166244,40.7003783,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Harlem Hospital, New York, New York, United States",-73.9395087,40.8143104,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Canton-Potsdam Hospital, Potsdam, New York, United States",-74.9825672,44.6764714,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Temple University Hospital, Philadelphia, Pennsylvania, United States",-75.1507582,40.0050435,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Sanford Health System, Sioux Falls, South Dakota, United States",-96.7431672,43.5356179,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,NCT04372186,"Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, United States",-88.0706558,43.1751518,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"University of California San Diego, La Jolla, California, United States",-117.2340135,32.8800604,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"eStudySite, La Mesa, California, United States",-117.0094774,32.7804422,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"David Geffen School of Medicine UCLA, Los Angeles, California, United States",-118.4423562,34.0642829,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Stanford University, Stanford, California, United States",-122.169719,37.4274745,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Denver Health Medical Center, Denver, Colorado, United States",-104.9910801,39.7282404,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"University of Miami Miller School of Medicine, Miami, Florida, United States",-80.2119928,25.7904064,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Rush University Medical Center, Chicago, Illinois, United States",-87.6674637,41.8747917,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"University of Chicago, Chicago, Illinois, United States",-87.5987133,41.7886079,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States",-90.9999851,30.442823,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Baystate Health System, Springfield, Massachusetts, United States",-72.6037013,42.1216158,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Mayo Clinic - PPDS, Rochester, Minnesota, United States",-92.4668833,44.0226255,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Hackensack University Medical Center, Hackensack, New Jersey, United States",-74.0564882,40.8840343,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Robert Wood Johnson University Hospital/Rutgers, New Brunswick, New Jersey, United States",-74.450131,40.4952121,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"James J Peters Veterans Administration Medical Center - NAVREF, Bronx, New York, United States",-73.9064045,40.8674032,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Duke University Medical Center, Durham, North Carolina, United States",-78.9371331,36.0058487,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Cleveland Clinic Foundation; Pulmonary, Allergy & Critical Care Medicine, Cleveland, Ohio, United States",-81.6211125,41.5025982,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Thomas Jefferson University, Philadelphia, Pennsylvania, United States",-75.1560106,39.9478658,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Baylor St. Luke's Medical Center, Houston, Texas, United States",-95.4006224,29.7077057,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Ben Taub General Hospital - HCHD, Houston, Texas, United States",-95.3933462,29.7106406,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Intermountain Medical Group, Saint George, Utah, United States",-113.5539707,37.0968017,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Intermountain LDS Hospital, Salt Lake City, Utah, United States",-111.87937,40.778402,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Evergreen Health Infectious Disease, Kirkland, Washington, United States",-122.1786164,47.715878,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Swedish Hospital Medical Center, Seattle, Washington, United States",-122.3795882,47.667469,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Hamilton General Hospital; Pharmacy, Hamilton, Ontario, Canada",-79.8540916,43.2624646,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada",-79.7743193,43.2218746,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"University Health Network, Toronto, Ontario, Canada",-79.3876181,43.6598777,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Clinical Research Institute of Montreal, Montreal, Quebec, Canada",-73.5761859,45.513589,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark",12.5667877,55.6960841,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Hvidovre Hospital, Hvidovre, Denmark",12.470292,55.648779,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Odense Universitetshospital, Odense C, Denmark",10.3675736,55.3850091,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Sjællands Universitetshospital, Roskilde, Roskilde, Denmark",12.0903485,55.6361646,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Centre Hospitalier Departemental de Vendee, La Roche Sur Yon, France",-1.4118805,46.6677714,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Centre Hospitalier et Universitaire de Limoges, Limoges, France",1.2357132,45.812311,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Hôpital de La Croix Rousse, Lyon, France",4.8308236,45.7818414,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Hotel Dieu - Nantes, Nantes, France",-1.5545498,47.2107575,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Hopital de la Pitie Salpetriere, Paris, France",2.3650429,48.8370792,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"HOPITAL COCHIN university hospital, Paris, France",2.3402667,48.8368937,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"CHRU de Tours, Pharmacie, Tours, France",0.6803135,47.389633,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Universitatsklinikum Dusseldorf, Dusseldorf, Germany",6.7888551,51.1987065,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Medizinische Hochschule Hannover, Hannover, Germany",9.8049569,52.3835661,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Universitatsklinikum Schleswig Holstein; Klinik fur Allgemeine Innere Medizin, Kiel, Germany",10.1406978,54.3298132,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Uniklinik Köln, Köln, Germany",6.9170635,50.9234823,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"LMU Klinikum der Universitat Munchen, Munchen, Germany",11.4699801,48.1106346,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Azienda Ospedaliera Dei Colli, Napoli, Campania, Italy",14.2207009,40.8677625,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Istituto Nazionale Malattie Infettive Lazzaro Spallanzani IRCCS, Roma, Lazio, Italy",12.4564793,41.866501,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"ASST Papa Giovanni XXIII; Dipartimento Interaziendale di Farmacia Clinica, Bergamo, Lombardia, Italy",9.638066,45.686107,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco, Milano, Lombardia, Italy",9.1230078,45.5192174,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Azienda Ospedaliera San Gerardo di Monza, Monza MI, Lombardia, Italy",9.2597899,45.6018705,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Fondazione IRCCS Policlinico San Matteo di Pavia; S.S. Fisiopatologia Respiratoria, Pavia, Lombardia, Italy",9.1488319,45.1962179,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Amphia Ziekenhuis, Breda, Netherlands",4.7628566,51.57417,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands",5.0789414,52.0249593,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Erasmus MC, Rotterdam, Netherlands",4.4703037,51.9112533,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Universitair Medisch Centrum Utrecht, Utrecht, Netherlands",5.1799131,52.0865646,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain",2.1042573,41.3448959,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Hospital Universitari Vall d'Hebron, Barcelona, Spain",2.142488,41.4283018,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Hospital Clinic de Barcelona, Barcelona, Spain",2.1523119,41.3894436,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Hospital Universitario La Paz, Madrid, Spain",-3.6873977,40.4811633,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Hospital Universitario Ramon y Cajal, Madrid, Spain",-3.6951156,40.4876043,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Hospital General Universitario Gregorio Maranon, Madrid, Spain",-3.6724986,40.4185038,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Hospital Universitario HM Sanchinarro-CIOCC, Madrid, Spain",-3.6667259,40.4902031,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Greater Glasgow and Clyde Health Board, Glasgow, United Kingdom",-4.321016,55.883619,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom",-1.5528918,53.8025196,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"University College Hospital, London, United Kingdom",-0.1363551,51.5250834,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Royal Free Hospital, London, United Kingdom",-0.1659994,51.5531475,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"St George's Clinical Research Facility, London, United Kingdom",-0.2343059,51.516825,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Imperial College London, London, United Kingdom",-0.1748772,51.4987997,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"North Manchester General Hospital, Manchester, United Kingdom",-2.2301193,53.5184925,Tocilizumab
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,NCT04320615,"Salford Royal Hospital, Salford, United Kingdom",-2.3238955,53.487482,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Mayo Clinic - Arizona, Phoenix, Arizona, United States",-111.9544986,33.6583608,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Univ of AZ Coll of Med, Tucson, Arizona, United States",-110.9461054,32.2410865,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"St. Jude Medical Center, Fullerton, California, United States",-117.9272201,33.8943451,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"LAC + USC Medical Center, Los Angeles, California, United States",-118.2075585,34.0575334,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"USC Keck Medical Center of USC, Los Angeles, California, United States",-118.2016181,34.0621498,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Norwalk Hospital, Norwalk, Connecticut, United States",-73.4222749,41.1117461,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Medstar Georgetown University Hospital, Washington, District of Columbia, United States",-77.0751693,38.911464,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"University of Florida; Health Science Center, Jacksonville, Florida, United States",-81.6634784,30.347113,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Mayo Clinic, Jacksonville, Florida, United States",-81.4451456,30.2626481,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Advocate Christ Medical Center, Oak Lawn, Illinois, United States",-87.7327824,41.7217943,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Advocate Lutheran General Hospital, Park Ridge, Illinois, United States",-87.8476325,42.0385102,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"MedPharmics, Metairie, Louisiana, United States",-90.1810171,30.0105053,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"University of Maryland, Baltimore, Maryland, United States",-76.6257057,39.2892017,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Renown Institute for Heart & Vascular Health, Reno, Nevada, United States",-119.7952114,39.52552,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"St Joseph's Regional Medical Center, Wayne, New Jersey, United States",-74.1653704,40.9028953,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"SUNY Downstate Medical Center., Brooklyn, New York, United States",-73.9456988,40.6552934,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Jamaica Hospital Medical Center, Jamaica, New York, United States",-73.8166244,40.7003783,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Vassar Brothers Medical Center, Poughkeepsie, New York, United States",-73.9357942,41.6943079,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States",-80.2791958,36.1355052,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",-81.6060645,41.5052505,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Mercy St. Vincent Medical Center, Toledo, Ohio, United States",-83.5429045,41.6686144,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Lehigh Valley Health Network, Allentown, Pennsylvania, United States",-75.5241629,40.5667553,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Temple University Hospital, Philadelphia, Pennsylvania, United States",-75.1507582,40.0050435,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Allegheny Health Network (Pittsburg PA), Pittsburgh, Pennsylvania, United States",-80.0040318,40.4425172,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Medical University of South Carolina, Charleston, South Carolina, United States",-79.9478413,32.7850493,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Houston Methodist Hospital, Houston, Texas, United States",-95.399568,29.7106626,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Michael E. DeBakey VA Medical Center, Houston, Texas, United States",-95.3889215,29.7020838,Tocilizumab
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,NCT04363736,"Houston Methodist Sugar Land Hospital, Sugar Land, Texas, United States",-95.6309922,29.5891707,Tocilizumab
Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia,NCT04332913,"Ospedale San Salvatore, L'Aquila, Italy",13.3532128,42.3659463,Tocilizumab
Tocilizumab Treatment in Patients With COVID-19,NCT04363853,"National Cancer Institute of Mexico, Mexico city, Distrito Federal, Mexico",-99.1603831,19.2892389,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,NCT04409262,"eStudySite - Chula Vista - PPDS, Chula Vista, California, United States",-117.024154,32.6172649,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,NCT04409262,"Ochsner Clinic Foundation, New Orleans, Louisiana, United States",-90.1139717,30.0206297,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,NCT04409262,"Louisiana State University Health Sciences Center/Ochsner, Shreveport, Louisiana, United States",-93.7608764,32.4807365,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,NCT04409262,"Boston Medical Center, Boston, Massachusetts, United States",-71.0731311,42.3344959,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,NCT04409262,"Baystate Medical Center, Springfield, Massachusetts, United States",-72.6037013,42.1216158,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,NCT04409262,"St. Michael'S Medical Center, Newark, New Jersey, United States",-74.1752203,40.7443458,Tocilizumab
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,NCT04409262,"Intermountain LDS Hospital, Salt Lake City, Utah, United States",-111.87937,40.778402,Tocilizumab
Checkpoint Blockade in COVID-19 Pandemic,NCT04335305,"Hospital Quirónsalud Barcelona, Barcelona, Spain",2.1385079,41.415745,Tocilizumab
Checkpoint Blockade in COVID-19 Pandemic,NCT04335305,"Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",2.174314,41.4136997,Tocilizumab
Checkpoint Blockade in COVID-19 Pandemic,NCT04335305,"Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain",0.6134759,41.62665,Tocilizumab
Checkpoint Blockade in COVID-19 Pandemic,NCT04335305,"Hospital Universitario Ramón y Cajal, Madrid, Spain",-3.6951156,40.4876043,Tocilizumab
Checkpoint Blockade in COVID-19 Pandemic,NCT04335305,"Hospital Ruber Juan Bravo, Madrid, Spain",-3.6776538,40.4327229,Tocilizumab
Checkpoint Blockade in COVID-19 Pandemic,NCT04335305,"Hospital Ruber Internacional, Madrid, Spain",-3.7156662,40.4894832,Tocilizumab
Checkpoint Blockade in COVID-19 Pandemic,NCT04335305,"Hospital Arnau de Vilanova-Lliria, Valencia, Spain",-0.4033429,39.4907502,Tocilizumab
Checkpoint Blockade in COVID-19 Pandemic,NCT04335305,"Hospital Universitario Doctor Peset, Valencia, Spain",-0.393695,39.4524937,Tocilizumab
Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19,NCT04306705,"Tongji Hospital, Wuhan, Hubei, China",114.309504,30.552113,Tocilizumab
Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019,NCT04310228,"Guiqiang Wang, Beijing, Beijing, China",116.4073963,39.9041999,Tocilizumab
Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019,NCT04310228,"Peking University First Hospital, Beijing, Beijing, China",116.380416,39.931765,Tocilizumab
Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019,NCT04310228,"Ezhou Central Hospital, Wuhan, Hubei, China",114.8819099,30.3987825,Tocilizumab
Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019,NCT04310228,"Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China",114.305539,30.592849,Tocilizumab
Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019,NCT04310228,"Jinyintan Hospital of Wuhan, Wuhan, Hubei, China",114.2868443,30.6668794,Tocilizumab
Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019,NCT04310228,"Wuhan Pulmonary Hospital, Wuhan, Hubei, China",114.305539,30.592849,Tocilizumab
Tocilizumab for Patients With Cancer and COVID-19 Disease,NCT04370834,"National Cancer Institute, Rockville, Maryland, United States",-77.1974895,39.1036356,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"2nd Department of Critical Care Medicine, ATTIKON University Hospital, Athens, Haidari, Greece",23.6653306,38.016598,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"Intensive Care Unit, Ioannina University Hospital, Ioánnina, Ioannina, Greece",20.8424173,39.620779,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"Department of Internal Medicine, Patras University Hospital, Patras, Rion, Greece",21.7950459,38.2945759,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"Department of Internal Medicine, I PAMMAKARISTOS Hospital, Athens, Greece",23.7315473,38.014229,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"Intensive Care Unit, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S., Athens, Greece",23.769038,37.992309,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"1st Department of Pulmonary Medicine and Intensive Care Unit, Athens, Greece",23.7275388,37.9838096,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"Intensive Care Unit, General Hospital of Athens IPPOKRATEIO, Athens, Greece",23.75975,37.9836396,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"4th Department of Internal Medicine, Attikon University Hospital, Athens, Greece",23.6653306,38.016598,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"Intensive Care Unit, General Hospital ASKLEPIEIO Voulas, Athens, Greece",23.7547649,37.8480872,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"Intensive Care Unit, ""Latsio"", Thriasio Elefsis General Hospital, Elefsína, Greece",23.5323004,38.071821,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"Intensive Care Unit, ""Koutlimbaneio & Triantafylleio"" Larissa General Hospital, Larissa, Greece",NA,NA,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"Department of Internal Medicine, Larissa University Hospital, Larissa, Greece",22.4191254,39.6390224,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"Intensive Care Unit, AGIOS DIMITRIOS General Hospital of Thessaloniki, Thessaloniki, Greece",23.7295198,37.9357211,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"Intensive Care Unit, G. GENNIMATAS General Hospital of Thessaloniki, Thessaloniki, Greece",22.9586356,40.6372887,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"Intensive Care Unit, Theageneio Oncological Hospital of Thessaloniki, Thessaloniki, Greece",22.9444191,40.6400629,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"Intensive Care Unit, General Hospital of Thessaloniki IPPOKRATEIO, Thessaloniki, Greece",22.9617339,40.6116363,Tocilizumab
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,NCT04339712,"Department of Anesthesiology and Intensive Care Medicine, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece",22.9600672,40.629556,Tocilizumab
Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis,NCT04315480,"Università Politecnica delle Marche, Ancona, AN, Italy",13.5139647,43.6173812,Tocilizumab
Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,NCT04333914,"Centre Léon Bérard, Lyon, Rhône, France",4.8777169,45.7412874,Tocilizumab
Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,NCT04333914,"CHU Clermont Ferrand, Clermont Ferrand, France",NA,NA,Tocilizumab
Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,NCT04333914,"Centre Oscar Lambret, Lille, France",3.0325736,50.6124605,Tocilizumab
Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,NCT04333914,"AP-HP Hôpital Saint Antoine, Paris, France",2.3827263,48.8488116,Tocilizumab
Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,NCT04333914,"AP-HP La Pitié Salpétrière, Paris, France",2.3650429,48.8370792,Tocilizumab
Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,NCT04333914,"Hôpital Saint-Joseph, Paris, France",2.309933,48.829771,Tocilizumab
Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,NCT04333914,"AP-HP Tenon, Paris, France",2.4019105,48.8661347,Tocilizumab
Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,NCT04333914,"AP-HP Hôpital Bichat Claude Bernard, Paris, France",2.3317094,48.8988449,Tocilizumab
Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,NCT04333914,"GH Diaconesses Croix Saint Simon, Paris, France",2.4087816,48.8541165,Tocilizumab
Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,NCT04333914,"Gustave Roussy, Villejuif, France",2.3484483,48.7942588,Tocilizumab
Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection),NCT04361552,"Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States",-84.3194393,33.7928615,Tocilizumab
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),NCT04380519,"Federal State Budget Institution ""National Medical Surgery Center named after N.I. Pirogov"" of Ministry of Health of Russian Federation, Moscow, Russian Federation",37.6172999,55.755826,Tocilizumab
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),NCT04380519,"State Budget Healthcare Institution ""City Clinical Hospital № 15 named after O.M. Filatov"" of Moscow City Healthcare Department, Moscow, Russian Federation",37.6172999,55.755826,Tocilizumab
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),NCT04380519,"Federal State Budgetary Institution ""Federal Center for Cerebrovascular Pathology and Stroke"" of the Ministry of Health of the Russian Federation, Moscow, Russian Federation",37.6172999,55.755826,Tocilizumab
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),NCT04380519,"Federal State Autonomous Education Insitution of High Education the First Moscow State Medical University named after I.M. Sechenov of Ministry of Healthcare of Russian Federation (Sechenov University), Moscow, Russian Federation",37.571717,55.731551,Tocilizumab
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),NCT04380519,"Federal State Budget Institution ""National Medicine Research Center on Cardiology"" By Ministry of Healthcare of Russian Federation, Moscow, Russian Federation",37.6172999,55.755826,Tocilizumab
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),NCT04380519,"State Budget Institution of Healthcare ""City Clinical Hospital #52"", Moscow City Healthcare Department, Moscow, Russian Federation",37.8074627,55.7984686,Tocilizumab
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),NCT04380519,"Moscow State Budget Institution of Healthcare ""Scientific Research Institute of Emergency Medicine named after N.V. Sklifosovsky of Moscow Department of Healthcare"", Moscow, Russian Federation",37.5286696,55.7039349,Tocilizumab
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),NCT04380519,"State Budget Healthcare Institution ""City Clinical Hospital #40"", Moscow City Healthcare Department, ""Communarca"" Division, Moscow, Russian Federation",37.8074627,55.7984686,Tocilizumab
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),NCT04380519,"АО ""State Company ""Medsi"" based on Clinical Hospital №1"", Moscow, Russian Federation",37.6172999,55.755826,Tocilizumab
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),NCT04380519,"Saint Petersburg State Budget Institution of Healthcare ""Clinical infectious diseases hospital named after S.P. Botkin"", Saint Petersburg, Russian Federation",30.3609096,59.9310584,Tocilizumab
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),NCT04380519,"Saint-Petersburg State Budget Institution of Healthcare ""City Hospital №40"", Saint Petersburg, Russian Federation",30.3609096,59.9310584,Tocilizumab
Treatment of COVID-19 Patients With Anti-interleukin Drugs,NCT04330638,"AZ Sint-Jan Brugge, Brugge, Belgium",3.1930172,51.2208468,Tocilizumab
Treatment of COVID-19 Patients With Anti-interleukin Drugs,NCT04330638,"University Hospital Saint-Pierre, Brussels, Belgium",4.345909,50.8344868,Tocilizumab
Treatment of COVID-19 Patients With Anti-interleukin Drugs,NCT04330638,"Erasmus University Hospital, Brussels, Belgium",4.265892,50.813446,Tocilizumab
Treatment of COVID-19 Patients With Anti-interleukin Drugs,NCT04330638,"University Hospital Saint-Luc, Brussels, Belgium",4.4520234,50.8529013,Tocilizumab
Treatment of COVID-19 Patients With Anti-interleukin Drugs,NCT04330638,"University Hospital Antwerp, Edegem, Belgium",4.4108109,51.157693,Tocilizumab
Treatment of COVID-19 Patients With Anti-interleukin Drugs,NCT04330638,"Ziekenhuis Oost-Limurg, Genk, Belgium",5.517904,50.957107,Tocilizumab
Treatment of COVID-19 Patients With Anti-interleukin Drugs,NCT04330638,"AZ Sint-Lucas, Gent, Belgium",3.7217947,51.0601558,Tocilizumab
Treatment of COVID-19 Patients With Anti-interleukin Drugs,NCT04330638,"University Hospital Ghent, Gent, Belgium",3.7261488,51.0243757,Tocilizumab
Treatment of COVID-19 Patients With Anti-interleukin Drugs,NCT04330638,"Jessa ZH, Hasselt, Belgium",5.3473957,50.9085411,Tocilizumab
Treatment of COVID-19 Patients With Anti-interleukin Drugs,NCT04330638,"University Hospital Brussels, Jette, Belgium",4.3086096,50.8878094,Tocilizumab
Treatment of COVID-19 Patients With Anti-interleukin Drugs,NCT04330638,"CHU Tivoli, La Louvière, Belgium",4.2076091,50.477916,Tocilizumab
Treatment of COVID-19 Patients With Anti-interleukin Drugs,NCT04330638,"CHR de la Citadelle, Liège, Belgium",5.5778565,50.6521064,Tocilizumab
Treatment of COVID-19 Patients With Anti-interleukin Drugs,NCT04330638,"University Hospital Liège, Liège, Belgium",5.5919769,50.6459547,Tocilizumab
Treatment of COVID-19 Patients With Anti-interleukin Drugs,NCT04330638,"Cliniques Saint-Pierre Ottignies, Ottignies-Louvain-la-Neuve, Belgium",4.5609799,50.667795,Tocilizumab
Treatment of COVID-19 Patients With Anti-interleukin Drugs,NCT04330638,"AZ Delta, Roeselare, Belgium",3.1233251,50.9539257,Tocilizumab
Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure,NCT04322773,"Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark",12.5401313,55.7140142,Tocilizumab
Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure,NCT04322773,"Hillerød Hospital, Hillerød, Denmark",12.326221,55.930868,Tocilizumab
Randomised Evaluation of COVID-19 Therapy,NCT04381936,"Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom",-1.2151574,51.7516232,Tocilizumab
CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),NCT04331808,"APHP- Hopital Tenon, Paris, France",2.4019105,48.8661347,Tocilizumab
CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),NCT04331808,"APHP - Beaujon, Paris, France",2.3083004,48.9082554,Tocilizumab
CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),NCT04331808,"APHP - Bichat, Paris, France",2.3317094,48.8988449,Tocilizumab
CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),NCT04331808,"APHP - Hopital Necker, Paris, France",2.3147044,48.845868,Tocilizumab
CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),NCT04331808,"APHP - Pitié Salpêtrière, Paris, France",2.3650429,48.8370792,Tocilizumab
CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),NCT04331808,"APHP - Saint Louis, Paris, France",2.3697699,48.8734065,Tocilizumab
CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),NCT04331808,"CHU Strasbourg, Strasbourg, France",7.7071667,48.5929237,Tocilizumab
CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),NCT04331808,"Institut Gustave Roussy, Villejuif, France",2.3484483,48.7942588,Tocilizumab
Factors Associated With Clinical Outcomes in Patients Hospitalized for Covid-19 in GHT-93 Est,NCT04366206,"Centre Hospitalier Intercommunal Robert Ballanger, Aulnay-sous-Bois, France",2.523274,48.9545206,Tocilizumab
Factors Associated With Clinical Outcomes in Patients Hospitalized for Covid-19 in GHT-93 Est,NCT04366206,"Groupe Hospitalier Pitie Salpetriere, Paris, France",2.3650429,48.8370792,Tocilizumab
Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients,NCT04409522,"Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of",51.3435135,35.7091321,Tocilizumab
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Hospital Universitario de Neiva, Neiva, Huila, Colombia",-75.2811942,2.9321351,Tocilizumab
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Clínica Reina Sofía, Bogotá, Colombia",-74.0519893,4.7068994,Tocilizumab
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Fundacion Cardio Infantil, Bogotá, Colombia",-74.0345157,4.7413984,Tocilizumab
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Hospital Universitario San Ignacio, Bogotá, Colombia",-74.0640042,4.6282546,Tocilizumab
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Clinica Universitaria Colombia, Bogotá, Colombia",-74.1065512,4.6482242,Tocilizumab
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,NCT04359095,"Hospital Universitario Nacional de Colombia, Bogotá, Colombia",-74.0957156,4.6489485,Tocilizumab
A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19,NCT04347031,"Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation",37.6172999,55.755826,Tocilizumab
Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study,NCT04365764,"Centre Hospitalier Intercommunal Robert Ballanger, Aulnay-sous-Bois, France",2.523274,48.9545206,Tocilizumab
Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study,NCT04365764,"Centre Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France",2.5720537,48.8984523,Tocilizumab
Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure,NCT04388514,"Dott. Amato De Monte, Udine, Italy",13.1207067,46.2170583,Tocilizumab
Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19,NCT04380818,"Hospital Sant Joan de Reus, Reus, Tarragona, Spain",1.1232334,41.1443624,Tocilizumab
Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19,NCT04380818,"Hospital Del Mar, Barcelona, Spain",2.1941912,41.3838907,Tocilizumab
Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19,NCT04380818,"Hospital Universitario Madrid Sanchinarro, Madrid, Spain",-3.6667259,40.4902031,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"St Vincent's Hospital Sydney, Sydney, New South Wales, Australia",151.2207522,-33.8805454,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Royal Prince Alfred Hospital, Sydney, New South Wales, Australia",151.1829669,-33.8891822,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Royal North Shore Hospital, Sydney, New South Wales, Australia",151.1918521,-33.8214962,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Nepean Hospital, Sydney, New South Wales, Australia",150.7137515,-33.7588094,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Wollongong Hospital, Sydney, New South Wales, Australia",150.88353,-34.42476,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Royal Darwin Hospital,, Darwin, Northern Territory, Australia",130.882915,-12.3554775,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Sunshine Coast University Hospital, Birtinya, Queensland, Australia",153.1137558,-26.7468526,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Princess Alexandra Hospital, Brisbane, Queensland, Australia",153.0332192,-27.4990274,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Logan Hospital, Brisbane, Queensland, Australia",153.1418031,-27.6700261,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Toowoomba Hospital, Toowoomba, Queensland, Australia",151.9442798,-27.5698357,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"The Queen Elizabeth Hospital, Adelaide, South Australia, Australia",138.5330755,-34.8837417,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Bendigo Hospital, Bendigo, Victoria, Australia",144.280769,-36.749617,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"University Hosptial Geelong, Geelong, Victoria, Australia",144.3656239,-38.1512248,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"The Alfred Hospital, Melbourne, Victoria, Australia",144.9819197,-37.8456704,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Royal Melbourne Hospital, Melbourne, Victoria, Australia",144.95617,-37.7989153,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia",144.9750364,-37.807357,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Royal Perth Hospital, Perth, Western Australia, Australia",115.8663522,-31.9537557,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Sir Charles Gairdner Hospital, Perth, Western Australia, Australia",115.8170819,-31.9669399,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"St John of God Hospital Midland, Perth, Western Australia, Australia",116.0071519,-31.8945381,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Fiona Stanley Hospital, Perth, Western Australia, Australia",115.8460302,-32.070223,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"St John of God Hospital Murdoch, Perth, Western Australia, Australia",115.8448198,-32.0679279,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"AZ Sint-Jan, Brugge, Belgium",3.1934588,51.2201147,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium",4.4401814,50.430972,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Universitair Ziekenhuis Antwerp, Edegem, Belgium",4.4108109,51.157693,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Universitair Ziekenhuis Gent, Gent, Belgium",3.7261488,51.0243757,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"St. Joseph's Healthcare Hamilton, Hamilton, Canada",-79.8702177,43.2491399,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Canada",-71.9239001,45.398023,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"St. Michael's Hospital Unity Health Toronto, Toronto, Canada",-79.3776369,43.6529691,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"General County Hospital Požega, Požega, Croatia",17.699313,45.34407,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"University Hospital Centre Zagreb, Zagreb, Croatia",16.005712,45.8247665,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"University Hospital for Infectious Diseases, Zagreb, Croatia",15.9801721,45.8297653,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany",13.3214126,52.4426162,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany",13.3766245,52.5264618,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Vivantes Klinikum Neukölln, Berlin, Germany",13.4584758,52.4390139,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Universitätsklinikum Köln, Cologne, Germany",6.9170635,50.9234823,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Universitätsklinikum Frankfurt, Frankfurt, Germany",8.6616969,50.0951726,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany",9.974533,53.5908116,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Medizinische Hochschule Hannover, Hannover, Germany",9.8049569,52.3835661,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Universitätsklinikum Jena, Jena, Germany",11.5787572,50.9289028,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Universitätsklinikum Leipzig, Leipzig, Germany",12.3865502,51.3309373,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Universitäts Klinikum Tübingen, Tübingen, Germany",9.0398494,48.529687,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Universitätsklinikum Würzburg, Würzburg, Germany",9.9583849,49.8071108,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Jósa András County Hospital, Nyíregyháza, Hungary",21.7298853,47.9505018,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary",17.9104293,47.090947,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Almási Balogh Pál Kórház, Ózd, Hungary",20.2916106,48.2092299,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Beaumont Hospital, Dublin, Ireland",-6.2233019,53.3904777,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"St. Vincent's University Hospital, Dublin, Ireland",-6.214048,53.31699,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"University Hospital Galway, Galway, Ireland",-9.066112,53.276846,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Meander Medisch Centrum, Amersfoort, Netherlands",5.3698679,52.1706432,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands",5.277171,51.6850355,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Martini Hospital Groningen, Groningen, Netherlands",6.5517301,53.1916514,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"University Medical Center Groningen, Groningen, Netherlands",6.5770261,53.220974,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Leiden University Medical Center, Leiden, Netherlands",4.4785036,52.1660315,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands",5.830246,51.817376,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Radboud University Medical Center, Nijmegen, Netherlands",5.8611812,51.8235728,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"University Medical Center Utrecht, Utrecht, Netherlands",5.1799131,52.0865646,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"North Shore Hospital, Auckland, New Zealand",174.7573882,-36.7811891,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"CVICU, Auckland City Hospital, Auckland, New Zealand",174.7691264,-36.8604597,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"DCCM, Auckland City Hospital, Auckland, New Zealand",174.7695893,-36.8605068,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Middlemore Hospital, Auckland, New Zealand",174.839542,-36.96339,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Christchurch Hospital, Christchurch, New Zealand",172.625825,-43.534003,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Waikato Hospital, Hamilton, New Zealand",175.2824626,-37.8050951,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Rotorua Hospital, Rotorua, New Zealand",176.248148,-38.131112,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Tauranga Hospital, Tauranga, New Zealand",176.1479153,-37.7079139,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Wellington Regional Hospital, Wellington, New Zealand",174.77937,-41.3082838,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Whangarei Hospital, Whangarei, New Zealand",174.3031392,-35.7350292,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Centro Hospitalar do Medio Tejo, Abrantes, Portugal",-8.1985734,39.4560473,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Hospital Lusíadas Lisbon, Lisboa, Portugal",-9.1795052,38.7493782,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Clinical Hospital of Infectious and Tropical Diseases ""Dr. Victor Babes"", Bucharest, Romania",26.1025384,44.4267674,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain",2.1940517,41.3853788,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Hospital Universitario Reina Sofia, Córdoba, Spain",-4.7977996,37.8677597,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom",-1.1111343,51.2803791,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Southmead Hospital, Bristol, United Kingdom",-2.5916111,51.4968176,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"University Hospital Coventry, Coventry, United Kingdom",-1.4376872,52.4211586,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Darlington Memorial Hospital, Darlington, United Kingdom",-1.5643608,54.530337,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"University Hospital of North Durham, Durham, United Kingdom",-1.5933009,54.7885266,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom",-1.5528918,53.8025196,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom",0.4840182,51.2750079,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"The James Cook University Hospital, Middlesbrough, United Kingdom",-1.2146772,54.5512379,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Milton Keynes University Hospital, Milton Keynes, United Kingdom",-0.7357762,52.0269973,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Northampton General Hospital, Northampton, United Kingdom",-0.8842779,52.2361366,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom",-1.1850038,52.9435955,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Poole Hospital NHS Foundation Trust, Poole, United Kingdom",-1.9737732,50.7213346,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom",-1.0700809,50.849983,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Royal Berkshire Hospital, Reading, United Kingdom",-0.9581844,51.4492924,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"University Hospital of North Tees, Stockton-on-Tees, United Kingdom",-1.3472709,54.5824968,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Royal Cornwall Hospital, Truro, United Kingdom",-5.0922396,50.2662301,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, United Kingdom",0.3069464,51.1483335,Tocilizumab
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",NCT02735707,"York Hospital, York, United Kingdom",-1.0835656,53.9699889,Tocilizumab
The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol,NCT04349410,"FHHI-OI-Camelot; QME, Los Angeles, California, United States",-118.4595285,34.0501689,Tocilizumab
Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial,NCT04374539,"Hospital Clinic i Provincial de Barcelona, Barcelona, Spain",2.1523119,41.3894436,Tocilizumab
An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19,NCT04346693,"Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation",37.6172999,55.755826,Tocilizumab
Study of Open Label Losartan in COVID-19,NCT04335123,"University of Kansas Medical Center, Kansas City, Kansas, United States",-94.6113987,39.05635,Tocilizumab
Ultra Low Doses of Therapy With Radiation Applicated to COVID-19,NCT04394182,"Hospital La Milagrosa, GenesisCare, Madrid, Spain",-3.6959039,40.4369834,Tocilizumab
Ultra Low Doses of Therapy With Radiation Applicated to COVID-19,NCT04394182,"Hospital Vithas Valencia Consuelo, Valencia, Spain",-0.3867362,39.4607499,Tocilizumab
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,NCT04366245,"Hospital U. Jerez de la Frontera, Jerez de la Frontera, Cádiz, Spain",-6.1486211,36.699219,Tocilizumab
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,NCT04366245,"Hospital U. Puerto Real, Puerto Real, Cádiz, Spain",-6.1515222,36.5200097,Tocilizumab
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,NCT04366245,"Hospital Costa del Sol, Marbella, Málaga, Spain",-4.827745,36.5079652,Tocilizumab
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,NCT04366245,"Hospital U. Torrecárdenas, Almería, Spain",-2.4411846,36.8626932,Tocilizumab
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,NCT04366245,"Hospital U. Puerta del Mar, Cádiz, Spain",-6.2782299,36.5089533,Tocilizumab
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,NCT04366245,"Hospital U. Virgen de las Nieves, Granada, Spain",-3.6099419,37.1885496,Tocilizumab
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,NCT04366245,"Hospital U. San Cecilio, Granada, Spain",-3.6050952,37.1466315,Tocilizumab
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,NCT04366245,"Hospital Juan Ramón Jiménez, Huelva, Spain",-6.926967,37.2798933,Tocilizumab
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,NCT04366245,"Hospital Regional U. de Málaga, Málaga, Spain",-4.4498416,36.7231736,Tocilizumab
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,NCT04366245,"Hospital U. Virgen de la Victoria, Málaga, Spain",-4.4780498,36.7183379,Tocilizumab
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,NCT04366245,"Hospital Unversitario Virgen Macarena, Sevilla, Spain",-5.986478,37.4065718,Tocilizumab
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,NCT04366245,"Hospital Universitario Virgen del Rocío, Sevilla, Spain",-5.9803696,37.3618418,Tocilizumab
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,NCT04366245,"Hospital U. Nuestra Señora de Valme, Sevilla, Spain",-5.9712578,37.3188416,Tocilizumab
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,NCT04366245,"Hospital San Juan de Dios, Sevilla, Spain",-5.9691386,37.3816501,Tocilizumab
Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease,NCT04392414,"Federal Research Clinical Center of Federal Medical & Biological Agency, Moscow, Russian Federation",-77.1043789,39.0025272,Tocilizumab
Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19,NCT04414631,"University Hospital Basel, Division of Internal Medicine, Basel, Switzerland",7.5830579,47.5621796,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States",-92.2923228,34.7390944,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Colorado University Denver, Aurora, Colorado, United States",-105.002304,39.7457714,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Alfred I. DuPont Hospital for Children, Wilmington, Delaware, United States",-75.5552234,39.7793465,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"University of Florida Jacksonville Shands Medical Center, Jacksonville, Florida, United States",-81.6641309,30.3485024,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Kapiolani Womens and Childrens Medical Center, Honolulu, Hawaii, United States",-157.8334591,21.2998428,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States",-87.6218344,41.8962223,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Riley Hospital for Children at Indiana University, Indianapolis, Indiana, United States",-86.1811403,39.7765068,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"University of Kansas Medical Center, Kansas City, Kansas, United States",-94.6113987,39.05635,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Wesley Medical Center, Wichita, Kansas, United States",-97.2981833,37.6953199,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"University of Louisville Norton Childrens Hospital, Louisville, Kentucky, United States",-85.7494773,38.2482108,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Tulane University Health Science Center, New Orleans, Louisiana, United States",-90.0791663,29.9529352,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Ochsner Baptist Clinical Trials Unit, New Orleans, Louisiana, United States",-90.1043211,29.9376843,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"University of Minnesota, Minneapolis, Minnesota, United States",-93.2277285,44.97399,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"University of Mississippi Medical Center, Jackson, Mississippi, United States",-90.1736583,32.3299207,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Childrens Mercy Hospital, Kansas City, Missouri, United States",-94.5771759,39.0838789,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"University of Nebraska Medical Center, Omaha, Nebraska, United States",-95.9759165,41.2548549,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States",-72.2729872,43.675364,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"University of New Mexico Health Science Center, Albuquerque, New Mexico, United States",-106.6182356,35.0903535,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Kravis Children's Hospital at Mt. Sinai, New York, New York, United States",-73.953917,40.7900948,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States",-79.0469134,35.9049122,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Duke University Health System, Durham, North Carolina, United States",-78.9375709,36.0070331,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States",-84.5014413,39.1406343,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Board of Regents of the University of Oklahoma, Oklahoma City, Oklahoma, United States",-97.5816919,35.5306526,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Oregon Health and Science University, Portland, Oregon, United States",-122.6891258,45.4963132,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Rhode Island Hospital, Providence, Rhode Island, United States",-71.4110581,41.8090573,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Medical University of South Carolina Children's Hospital, Charleston, South Carolina, United States",-79.9508927,32.7847341,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"University of South Carolina, Columbia, South Carolina, United States",-81.0299186,33.9937575,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States",-86.8024888,36.1393475,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Dell Children's Medical Center of Central Texas, Austin, Texas, United States",-97.7073463,30.3034562,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Seattle Children's Hospital, Seattle, Washington, United States",-122.2819821,47.6628416,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"University Wisconsin, Madison, Wisconsin, United States",-89.4124875,43.076592,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Medical College of Wisconsin, Milwaukee, Wisconsin, United States",-88.02212,43.0429926,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada",-75.652152,45.4007668,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"The Hospital for Sick Children, Toronto, Ontario, Canada",-79.3873039,43.6573229,Tocilizumab
"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",NCT04278404,"CHU Sainte-Justine, Montréal, Quebec, Canada",-73.6239743,45.5032538,Tocilizumab